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Preface
Barbara A. Ray and Monique C. Braude
The history of drug abuse research shares with other sciences a
relative paucity of knowledge about females in particular and
about gender effects in general. This bias in knowledge stems
from the tradition of using male subjects for animal and human
experiments and an unexamined assumption that gender is not an
important experimental variable.
The Public Health Service is now charged with correcting this
cumulated imbalance in knowledge, and the PHS Women's Task Force
has developed specific recommendations for achieving the goal,
including targets for the future of drug- and alcohol-related
research. The history and significance of the Task Force is here
described by Dr. Chatham, and mechanisms and guidelines for
correcting gaps in knowledge about new and marketed drugs are
referenced in Dr. Danello's overview of the Food and Drug
Administration and its role in drug-related research.
Among the culturally embedded but inaccurate assumptions about
gender is that reproductive functioning is somehow an entirely
female matter. Consideration must now be given to the possible
assault on both male and female gametes by drug and alcohol abuse.
Not only can the female ovum possibly be damaged by substance
abuse, but male sperm can likewise be damaged and subvert healthy
fetal development.
Another false assumption about gender is that sex differences are
relevant only to reproductive processes. Dr. Hamilton provides an
extensive and well-documented story of the many ways that gender
affects health, including the gonadal steroid influences on brain
neurochemical substrate. A host of new discoveries make it clear
that differences in brain structure and physiology exist that are
attributable to a masculine or feminine patterning of hormones
occurring at critical periods during development.
As the chapter by Dr. Baum makes quite clear, sex hormones are not
male or female, but interact at critical stages to produce pro-
found differences in anatomy and behavior. Dr. Baum leads us
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through an intricate trail of detection to show that, in the fer-
ret. It is ultimately estrogen that permits the formation of a
male brain nucleus that then seems to permit sensitivity to tes-
tosterone, leading to characteristic male behavior. Although
Dr. Baum describes brain dimorphism in the ferret, an extensive
literature is emerging that strongly suggests that brain di-
morphism exists between the human female and male.
For the purposes of scientific research, studying just women is as
meaningless as studying just men. Rather, gender as an experimen-
tal variable needs to become standard in studies of drug abuse and
drug effects. Dr. Mendelson shows us that the picture for women
and drug abuse changes markedly when nature and extent figures are
broken out for men and women separately. Looking only at how many
substance abusers are women, their problem seems small compared to
the numbers of men abusing drugs and alcohol. But among women
needing mental health support services, drug and alcohol abuse
problems rank second only to depressive illness. From a female
perspective, substance abuse appears as an important threat to
health.
Dr. Mello presents evidence indicating that women who suffer dys-
phoria associated with the menstrual cycle may self-medicate
during the dysphoric period. That the menstrual cycle involves
coordinated and repeated hormonal secretions in the central nerv-
ous system makes the female possibly a useful model for studying
drugs of abuse, as abused drugs typically act on central neural
events.
Going back to reanalyze epidemiologic data by gender, Dr. Clayton
uses NIDA's 1982 National Survey to show certain stable differ-
ences in drug use by gender as well as a trend toward convergence
in age-of-first-use for females and males. Dr. Clayton directs
our attention to the changing role of women in society and sees a
need to track how this may affect substance abuse patterns in the
future.
For the purpose of preventing drug abuse, it is important to
understand how societal, economic, and physiological pressures
differ for subpopulations. Several contributors address this
question. Dr. Gritz outlines the correlation between a post World
War II decision by cigarette manufacturers to target the female
consumer and a gradual increase in cigarette smoking by women,
beginning in their teens, at a time when men were decreasing their
smoking. Dr. Braude provides an overview of the many important
changes in biology and life circumstances that confront the older
woman, who composes approximately 60 percent of the elderly
population. Dr. Braude also points out the especially high risk
In this population of harmful effects resulting from the taking of
multiple medications that may have unknown and possibly dangerous
interactions. In a related chapter, Dr. Barry, drawing upon her
geriatric expertise, gives details of the changing response to
drugs that accompanies the aging process and how this differs for
men and women.
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Gender research is in its infancy and promises to challenge
accepted ideas as the accumulating data sort fact from fiction.
The NIDA conference on women and drugs and this monograph are one
step in the process of opening the scientific community to new
ideas and knowledge about gender as it relates to substance abuse.
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The PHS Task Force on
Women’s Health Issues
Lois Chatham
I have been asked to convey to you the background and significance
of the Public Health Service (PHS) Task Force on Women's Health
Issues. As background I would like to discuss the reasons why a
task force is created. It is my impression that a task force
usually is created to work on a specific, well-defined problem or
subject--hence the term task force. The establishment of such a
work group provides visibility and enables the appointing official
to cut across organizational lines for the purpose of pooling
resources. The creation of a task force also usually implies
speedy action.
A task force frequently is created in response to some perceived
emergency or threat. The event may be a national or regional
emergency, such as an outbreak of Legionnaire's disease, the
eruption of Mt. St. Helen, the flooding of Johnstown, Pennsyl-
vania, or, more recently, the outbreak of Acquired Immune
Deficiency Syndrome (AIDS). On the other hand, such a group may
be established in response to perceived political pressures such
as the concerns of the aging, the Vietnam veterans, the handi-
capped, or minority populations.
The PHS Task Force on Women's Health Issues obviously was not
created in response to an emergency health event. In fact,
women's overall health status, like the Nation's health, has
improved over the past decade. However, it also is apparent that
the treatment of many chronic diseases and devastating illnesses
has not improved significantly over the past decade.
Because the Task Force report was scheduled for submission to the
Assistant Secretary for Health in October prior to the 1984
Presidential election, many of us wondered if the Task Force had
been created in response to political pressure. However, this
concern proved unfounded. To the contrary, the Task Force was the
attempt of the Assistant Secretary for Health, Dr. Edward Brandt,
to direct the Public Health Service to reexamine its activities
for the purpose of significantly improving women's health.
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To assess the significance of a task force, one must examine the
organizational placement of the unit and the stature of the mem-
bers. One also must assess the resources allocated to the
activity. In this case, although no funds were provided, the
Office of the Assistant Secretary for Health assigned a staff
member to serve as Executive Secretary for the Task Force. It
also is significant that the Chairperson of the Task Force is the
highest ranking woman in the Public Health Service, namely, Ruth
Kirschstein, M.D., Director of the National Institute of General
Medical Sciences. Other Task Force members were appointed by the
respective PHS agency heads. All members, by virtue of organiza-
tional location or personal characteristics, were in a position to
speak for the agency they represented in matters of policy and
resources. This is essential to the effective operation of such a
unit.
A task force put together to work quickly on a single task faces
certain dangers. First, because of the singlemindedness of the
assignment, a task force may create organizational threats to
existing agencies that feel the work being performed lies within
their agency's scope of responsibility. Second, the task force
may make impractical or impossible recommendations because of
bureaucratic naivete. Third, the report may not be read by the
right people, or, if read, the recommendations may not be imple-
mented. To increase the likelihood that the recommendations of
the task force would be used, all recommendations were carefully
analyzed for feasibility and appropriateness by the organizational
units expected to implement them.
In October, 1984, the Task Force Report was submitted to the
Assistant Secretary for Health, Dr. Edward Brandt. In November,
1984, Dr. Brandt issued a memorandum to all Health and Human
Services (HHS) agency heads, directing them to develop plans for
implementing the Task Force recommendations. To ensure continuity
and oversight of these plans, in December, 1984, the Assistant
Secretary for Health established the Coordinating Committee on
Women's Health Issues. Thus, in June, 1985, agency representa-
tives reported for the first time to the Assistant Secretary for
Health on the progress being made to implement the Task Force
recommendations. These plans, in turn, will be reviewed by the
Coordinating Committee as the first step in providing a continuing
review of the implementation of the Task Force Report and Recom-
mendations.
To give you an historical perspective, the following lists have
been developed. These outline the history of the Task Force.
They outline its areas of responsibility and the recommendations
it has made. The chronological sequence of events is outlined
below:
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PHS TASK FORCE ON
WOMEN'S HEALTH ISSUES
1983
Summer
Dr. Edward Brandt, DHHS, Assistant Secretary for Health, appoints
Task Force.
PHS agencies assemble information on diseases/conditions:
Unique to women
More prevalent in women
More serious in women
Having different risk factors for women
Fall
Task Force establishes six committees.
1984
January-March
PHS Regional Offices hold public hearings.
April-August
Reports and recommendations are prepared and edited.
September
Executive Summary and Recommendations plans developed by PHS
agencies.
December
PHS Coordinating Committee on Women's Health Issues is
established.
1985
February
Volume I of Women's Health: Report of the Public Health Service
Task Force on Women's Health Issues published (USPHS 1985).
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M a y
Volume II of Women's Health report published (USPHS 1985).
The members of the Task Force encompassed all PHS agencies, as
follows:
Office of Disease Prevention and Health Promotion (OPDHP)
Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA)
Centers for Disease Control (CDC)
Food and Drug Administration (FDA)
Office of Public Affairs (OPA)
National Institutes of Health (NIH)
Health Resources and Services Administration (HRSA)
These agencies have divergent responsibilities, all of which
address the broad mandate of the Public Health Service. For ease
in implementation, recommendations were grouped according to which
of the six PHS missions they most clearly addressed. The PHS
missions are:
I. Promoting a Safe and Healthful Physical and Social
Environment
II. Providing Services for the Prevention and Treatment of
Illness
III. Conducting Research and Evaluation
IV. Recruiting and Training of Health Care Personnel
V. Educating and Informing the Public and Disseminating
Research Information
VI. Designing Guidance for Legislative and Regulatory Measures
Similarly, for ease in accomplishing the task, subcommittees were
formed to write reports for the full Task Force. After much
thought, six subcommittees were formed as outlined below:
Social Factors Affecting Women's Health
Women's Physical Health and Well-Being
Health Concerns of Older Women
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Issues Related to Alcohol and Drug Abuse and the Mental Health
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of Women
Assessment of Women's Health Issues as Presented at Regional
Meetings
Inventory of Public Health Service Programs Related to Women's
Health
The first four are substantive in nature. The fifth subcommittee
report summarizes the recommendations made at the meetings held in
the PHS regional offices, and the sixth subcommittee report is a
repository of all relevant women's health activities and resources
identified during the life of the Task Force.
Since the Task Force was to address health issues of women in the
broadest sense, it became apparent that the Federal Government was
responsible for implementing only a portion of the recommenda-
tions. Indeed, if women's health issues were to be effectively
and efficiently addressed, the following sectors needed to be
involved:
The Public Health Service
Other Federal, State, and local government agencies
Private and voluntary organizations
Women themselves
Below, the recommendations are displayed within the six-part
mission of the Public Health Service.
I.
A.
B.
II.
A.
B.
PROMOTING A SAFE AND HEALTHFUL PHYSICAL AND SOCIAL
ENVIRONMENT
Use the law and regulations to ensure a safe, healthful
physical and social environment for all.
Encourage women to learn about health issues and take
personal and political action to Improve their health.
PROVIDING SERVICES FOR THE PREVENTION AND TREATMENT OF
ILLNESS
Make chronic disease management a priority for the Public
Health Service.
Increase access to health care for women who are
underinsured, elderly, or isolated.
III.
A.
B.
C.
D.
E.
IV.
A.
B.
V.
A.
8.
C.
VI.
A.
B.
CONDUCTING RESEARCH AND EVALUATION
Expand research on conditions that are unique to women or
that are more prevalent in women.
Use longitudinal research to assess the interaction of
behavioral, social, and biological factors.
Collect and analyze health data by age, sex, and race.
Study workplace hazards for women.
Study how culture and socialization affect women's and men's
health differently.
RECRUITING AND TRAINING OF HEALTH CARE PERSONNEL
Increase the number of women in key health positions in
services, research, administration, and education.
Address continuing education programs in health to women's
needs.
EDUCATING AND INFORMING THE PUBLIC AND DISSEMINATING
RESEARCH INFORMATION
Communicate the importance of a healthful lifestyle through
outreach programs.
Organize a group from television, films, publishing, and
advertising to examine the effects of media images on
women's health.
Disseminate, via the Public Health Service, up-to-date
research information.
DESIGNING GUIDANCE FOR LEGISLATIVE AND REGULATORY MEASURES
Encourage organizations interested in women's well-being to
keep informed, promote information exchange and education,
and advocate improved health conditions for women.
Use law and regulations to ensure a safe, healthful physical
and social environment for all.
Finally, the Task Force report consists of many recommendations
beyond the 16 displayed above. Since the purpose of this meeting
is to look at women's health as affected by drug and alcohol
abuse, some additional recommendations have been identified as a
useful framework for conceptualizing presentations and potential
recommendations which may come from this conference.
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SPECIAL EFFORTS SHOULD BE MADE TO GAIN KNOWLEDGE ABOUT THOSE
DISEASES RELATED TO ALCOHOL AND DRUG ABUSE, AND ABOUT MENTAL
ILLNESSES OF IMPORTANCE TO WOMEN, BY THE INITIATION OF:
(1) Research to study depression in women when it occurs alone or
in conjunction with alcohol or drug abuse problems.
(2) Studies of the significant factors related to the onset,
continuation, and cessation of smoking, drinking, and drug
taking by women.
(3) Studies of the role of the family and of cultural attitudes
in the maintenance of mental health or the development of
mental illness, as well as in the use or misuse of alcohol,
drugs, and tobacco.
A SYSTEMATIC EFFORT MUST BE MADE TO ADDRESS ISSUES RELATING TO
GENDER BIAS IN RESEARCH AND CLINICAL PRACTICE THAT LEAD TO
INADEQUATE ATTENTION TO THE NEEDS OF WOMEN.
Ways to effect such change include:
(1) The issuance of a comprehensive Public Health Service policy
directing all operating units to review their research guide-
lines to ensure that sex differences are routinely studied,
wherever feasible. Such instructions should be included in
grant application kits.
(2) The requirement that postmarketing surveillance of all
prescription drugs should include reporting of the adverse
effects in women of drug interactions with alcohol, commonly
used psychotherapeutic drugs, and drugs commonly used in
relation to hormonal changes in women.
(3) The requirement that adequate numbers of women be included in
clinical trials of drugs that will be used by women, and that
results be separately reported by gender for all new drugs
that are to be recommended for use by women.
(4) The commissioning of an interdisciplinary panel of senior
scientists, including women, to review existing research and
research methodology to develop a comprehensive plan for
addressing any gender bias identified in research in general,
but in particular in alcohol, drug abuse, and mental health
research.
(5) The establishment of a task force to review mental health
issues related to women and to make recommendations for
change in the Fourth Revision of the Diagnostic and
Statistical Manual (DSM IV) of the American Psychiatric
Association (APA), in order to promote adequate diagnosis
and treatment of women with alcohol, drug abuse, and mental
health problems. Such a task force should work closely with
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the APA Task Force on Nomenclature and Statistics. In
addition, a similar review mechanism should be established
for the International Classification of Diseases (ICD-10).
This summarizes the progress and significance of the PHS Task
Force on Women's Health Issues. I am confident that our meeting
and collaborative publication reflect an awareness that research
on drug and alcohol use by women is crucial to improving the
health status of women. With the impetus provided by the Task
Force Report, it is anticipated that the research community will
be stimulated to explore aspects of women's health previously
neglected.
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FDA’s Perspective on Women
and Drugs
Mary Ann Danello
Many of you are probably familiar with the Food and Drug Adminis-
tration's (FDA) requirements for new drug approval. However, for
the benefit of those who are not as familiar with this process,
let me give you a brief overview as well as some idea of when
women are included in these clinical trials.
The FDA provides guidance for investigators performing clinical
evaluations of new drugs in an Agency publication entitled,
"General Considerations for Clinical Evaluation of Drugs" (HEW
publication no. FDA-77-3040). The purpose of this publication is
to present acceptable current approaches to the study of investi-
gational drugs in humans. The document, in part, contains recom-
mendations for clinical studies, which are recognized as desirable
approaches to be used in arriving at conclusions concerning the
safety and effectiveness of a new drug, and includes the following
basic information:
A description of institutional review boards (IRBs) and
principles of informed consent
Clinical trial design and analysis considerations
Selection of subjects
Numbers of and randomization of patients
Study control
Patient compliance
Dosage considerations
Drug dynamic studies
In addition to that document, there are 25 clinical guidelines
available concerning the design of adequate and well-controlled
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studies on different classes of drugs. These guidelines have been
developed largely or entirely by the FDA's advisory committees and
consultants.
The FDA's drug review and approval process involves two stages--
the investigational new drug application stage (IND) and the new
drug application stage (NDA). The IND process begins after animal
data on the drug have been collected and analyzed and the testing
in humans is ready to commence. Once an IND is submitted to the
FDA, and the Agency is satisfied that the study does not pose
unreasonable risks to human subjects, then the sponsor may begin
testing the drug in humans.
The testing of investigational drugs occurs in three phases:
PHASE 1
These are clinical pharmacologic studies which include the initial
introduction of the drug into humans and involve a range of about
20 to 80 persons in a trial. Phase 1 trials include early dose-
ranging studies as well as determination of toxicity levels and
pharmacologic effects. Drug dynamic and metabolic studies are
also considered to be Phase 1 clinical pharmacologic studies in
whichever stage of the clinical investigation they are performed.
It is recommended that females who are pregnant, or are at risk of
becoming pregnant, should be excluded from early dose-ranging
studies.
PHASE 2
These clinical investigations consist of controlled clinical
trials designed to demonstrate effectiveness and relative safety
of the investigational drug. These studies are normally performed
on a limited number (100 to 200) of closely monitored patients.
Women may be included in Phase 2 clinical trials if adequate
information on relative safety and efficacy has been amassed and
certain animal experiments described in the FDA animal reproduc-
tion guidelines (Segment 1 for females and Segment 2) have been
completed. These experiments determine the teratogenic potential
of the investigational drug. There are instances in which women
of childbearing potential may receive investigational drugs in the
absence of adequate reproduction studies in animals. These
include: the use of the drug as a lifesaving or life-prolonging
measure; use of the drug which belongs to a class of drugs the
teratogenic potential of which has already been determined; use of
women who may have been institutionalized for a time period
adequate to establish a nonpregnant state.
PHASE 3
These clinical trials are expanded controlled and uncontrolled
trials. They are performed after the drug's effectiveness has
been established (to a certain degree) and are intended to gather
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additional evidence of effectiveness for specific indications and
a more precise definition of drug-related adverse effects. Since
Phase 3 trials are large-scale trials, it is recommended that
women of childbearing age be included only if all three segments
of the FDA animal reproduction guidelines are completed to deter-
mine the teratogenic potential of the investigational drug. As
with Phase 2 trials, there are circumstances in which an investi-
gational drug may be administered to women in the absence of
adequate reproduction studies in animals.
Data from the Phase 1, 2, and 3 studies, as well as additional
information (supplements, amendments, progress reports, and
reviews), are compiled by the sponsoring pharmaceutical firm and
comprise the NDA (New Drug Application). After these data have
been analyzed and assessed by the FDA to determine that the inves-
tigational drug is safe and effective for what it claims to do,
the drug can be approved for marketing. Following the marketing
of a drug, the drug's sponsor should submit to the FDA reports on
adverse reactions, data from additional studies, or manufacturing
information.
PHASE 4
These studies are clinical trials which are undertaken after the
new drug has been marketed. Included in this category are:
additional studies to elucidate the incidence of adverse reac-
tions or to obtain more information on a pharmacologic effect;
large-scale, long-term morbidity or mortality studies;
clinical trials in a patient population not adequately studied
in the premarketing stage;
clinical trials for an indication for which the presumed drug,
once available, will be used; and
additional Phase 3-type trials to supplement premarketing data
where it has been deemed in the public interest to release a
drug for more widespread use prior to the acquisition of all
data normally obtained before marketing.
Subpopulations
While the Agency has developed separate guidelines for clinical
evaluation of drugs in infants and children and is in the process
of addressing some of the special problems of clinical evaluation
of drugs in the elderly, there are presently no similar guidelines
for women of childbearing potential. However, the "General Con-
siderations" publication includes a brief section on the inclusion
of women of childbearing potential in studies of investigational
drugs.
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The salient features of these general considerations are as
follows:
Women of childbearing potential should be excluded from the
earliest dose-ranging studies.
If adequate information on efficacy and relative safety data
are present (including certain animal reproduction studies),
women of childbearing potential may be included in Phase 2 and
Phase 3 trials.
Women of childbearing potential may receive Phase 2 or Phase 3
investigational drugs in the absence of adequate reproduction
studies in animals under certain circumstances (e.g., the drug
is lifesaving or life prolonging, or it belongs to a class of
drugs for which the animal teratogenic potential is known).
When an investigational drug for which there are no animal
reproduction data is used in women for the treatment of a
serious disease, the lack of animal data should be pointed out
and fully informed consent obtained.
Pregnancy tests should be performed prior to the introduction
of investigational drugs in women and they should be advised of
contraceptive measures.
For drugs that are absorbed systemically, transplacental pas-
sage of the drug and its secretion in milk should be assumed.
Fetal followup should be conducted in women who become pregnant
while on an investigational drug. Excretion of the drug or its
metabolites in the milk of lactating women should be deter-
mined, when feasible, prior to the use of the drug in nursing
mothers.
This is a brief overview of the FDA new drug approval process and
the avenues for testing drug effects on women and their offspring,
including the current considerations for the use of women in
clinical trials for investigational drugs. As you have seen,
women of childbearing age can be included in clinical trials, but
under a prescribed set of circumstances. Older women (i.e., post-
menopausal) can also be included in clinical trials for investiga-
tional drugs according to draft Agency guidelines for testing
drugs in the elderly.
FOOTNOTE
1Segments of FDA animal reproduction studies:
Segment 1 - Single generation studies to assess gonadal function,
estrous cycle, mating behavior, and early stages of
gestation
Segment 2 - Assessment of teratogenesis
12
Segment 3 - Effects of the investigational drug on the late fetal
development, labor, delivery, lactation, and health
of the newborn
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An Overview of the Clinical
Rationale for Advancing
Gender-Related
Psychopharmacology and Drug
Abuse Research
Jean A. Hamilton
Gender correlates with naturally occurring patterns of drug use,
misuse, and abuse (Russo et al. 1985). In studying gender as a
variable in clinical pharmacology, we must move beyond overly
simplistic laboratory studies of single agents and recognize the
drug combinations that women actually use. For example, women
frequently combine the use of drugs--legal and illegal--with the
use of exogenous steroid hormones, i.e., oral contraceptives or
estrogens for postmenopausal replacement therapy. These combi-
nations are sometimes used in conjunction with alcohol or ciga-
rettes, which are known to affect endogenous hormones (MacMahon et
al. 1982; Sepkovic et al. 1984). Certain drugs have side effects
that are known to alter the menstrual cycle or other gender-relat-
ed reproductive functioning (Mendelson and Mello, this volume).
Despite this evidence, which provides a clinical rationale for a
more gender-related pharmacology, investigators have too often
behaved as though these effects are trivial and do not merit sys-
tematic attention. That a gender-related blind spot may occur in
drug research is suggested, for example, by the relative neglect
of gender as a variable, even when there is evidence that gender
is related to the actual disease process (Raskin 1974; Kinney et
al. 1981; Hamilton and Parry 1983; Hamilton et al. 1984b).
One example of the biased attitudes that operate against the
appropriate recognition of gender as a research variable is the
preference for "basic" as opposed to "applied" advances in sci-
entific knowledge. Clinical pharmacologists have behaved as
though gender-related drug effects, even if they occurred, would
be "only metabolic." Implicit in this belief is the assumption
that gender-related effects will not help to clarify the basic
mechanisms of drug action.
While this belief may have been tenable in the previous decade, it
runs counter to the most recent evidence. For example, the exist-
ence of gender-related differences in brain structures--and per-
haps in localized functioning--could have consequences for the
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effects of certain drugs on the brain (Baum, this volume). More-
over, there is increasing evidence that gonadal steroids affect
the ongoing neurochemical substrate underlying the mechanisms of
drug action in the brain (Murphy and Hamilton 1983; Hamilton and
Conrad, in press). While speculative, these trends in the data
now provide a basic science rationale for gender-related drug re-
search, which reinforces the purely clinical argument.
In considering the implications for drug abuse research, I am
impressed that both prescription psychoactive drugs and drugs of
abuse are often used to alter the quality of our thinking and
experiences. As one example, for reasons that are not understood,
antidepressants are rarely drugs of abuse (while speculative, this
may be related to side effects, or to an effect of the initial
baseline in terms of mood), but alcohol, opiates, and stimulants
are likely to be used or abused in order to avoid dysphoria, if
not to actually self-medicate a clinically significant depression.
At least from the standpoint of regulating affect, this suggests a
certain degree of motivational overlap. In addition, several pre-
scription psychoactive drugs share with drugs of abuse some of the
side effects on reproductive functioning. From the perspective of
these observations, I will briefly review some of the gender-
related data for two types of psychoactive drugs, antidepressants
and antipsychotics.
My purpose in this chapter is to highlight gaps in knowledge and
to identify several methodological requirements for advancing
gender-related psychopharmacology. Many of these observations
will have parallels for drug abuse research. I will further ad-
dress some of the attitudinal and conceptual barriers to moving
gender-related methods into the mainstream of clinical psychophar-
macology and drug abuse research.
GENDER-RELATED DATA FOR SELECTED PSYCHOACTIVE DRUGS
Antidepressants
About 10 years ago, Raskin (1974) reviewed the existing data and
concluded that: "Although twice as many women as men are treated
for depression, the depression literature suggests that it is the
men rather than the women who benefit most from antidepressant
drugs." When I attempted to update Raskin's review, I was
especially interested in the literature on MAO-inhibiting anti-
depressants, due to the suggestion of sex-related differences in
responsivity in the animal literature. But my review of the
existing clinical data on phenelzine, a nonspecific MAO-inhibiting
antidepressant, demonstrated important gaps in knowledge, since
only 3 out of 25 studies (12 percent) tabulated the data by either
gender or age (Hamilton et al. 1984). It is likely that other
gender-related effects might be observed in psychopharmacology,
but without the adequate inclusion and reporting of gender as a
research variable, it is impossible to know (Hamilton and
Hirschfeld 1984).
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Also of interest with regard to possible abuse or misuse of stimu-
lants is Gerner's (1983) observation that amphetamine may be more
effective as an antidepressant in females or the elderly than in
males. This example highlights the need to clarify gender-related
effects in order to maximize therapeutic responsivity and to mini-
mize untoward side effects in subgroups that are defined by gender
and age.
Antipsychotics
As we reevaluate gender as a variable in psychopharmacology, the
literature on antipsychotics and tardive dyskinesia demonstrates
the need to clarify gender by age effects in the light of hormonal
effects. Tardive dyskinesia is a movement disorder that occurs in
association with the use of antipsychotic drugs. The well-known
gender difference in the distribution of this side effect (Tepper
and Haas 1979; Kane and Smith 1982) is confirmed even when con-
trolling for age; that is, the female excess is not simply an
artifact of comparing older women with younger males, since it
persists in studies with a similar male-female age distribution,
and it has also been observed in younger age groups (Brandon et
al. 1971; Degkwitz and Wenzel 1967).
There does not appear to be a simple or trivial explanation for
the gender-related difference in tardive dyskinesia. For example,
the finding is probably not simply a function of gender differ-
ences in absolute dosage (Odejide 1980; Simpson et al. 1978; Yassa
et al. 1983), relative dosage, length of drug use, or polypharmacy
(Simpson et al. 1978). Future studies of possible gender and hor-
monal effects on neuroleptic blood levels (Stevens 1973), optimal
dosages required for control of symptoms (Chouinard et al. 1980;
Seeman 1983), and subtype of movement disorder can clarify the
observed gender-related effects.
At present, the evidence for a hormonal account of the gender-
related distribution of tardive dyskinesia is mixed, but there is
some literature suggesting an effect of menstrual status and of
circulating levels of gonadal hormones (Stevens 1973). For exam-
ple, when the gonadal hormone, estrogen, is extremely high in
premenopausal women--as with oral contraceptive use (Barber et al.
1976) or during pregnancy--a choreiform movement disorder may
arise, perhaps from excess functioning of the brain neurotransmit-
ter, dopamine (Gordon et al. 1980; Klawans et al. 1980).
With menopause, estrogens diminish gradually, often over the
course of years. Moderate levels of estrogen are thought to be
protective for tardive dyskinesia, partly through a presynaptic
mechanism (Klawans et al. 1980). Particularly for women who have
been on antipsychotic medication, the loss of the protective ef-
fect of estrogen at menopause may, in effect, "unmask" tardive
dyskinesia. Although there is not an increase in the prevalence
of tardive dyskinesia in the menopausal age group, the greatest
increase in the severity of tardive dyskinesia does occur in the
forties and fifties Smith and Baldessarini 1980).
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Another investigational finding connecting tardive dyskinesia with
estrogen levels is that exogenous estrogens improve dyskinesia in
both animals (Gordon et al. 1980) and humans. For example, stand-
ard doses of Premarin (.625 mg/d) resulted in marked improvement
in a repeated on-off clinical trial involving two women
(Villeneuve et al. 1978; Bedard et al. 1977).
METHODOLOGICAL REQUIREMENTS FOR ADVANCING GENDER-RELATED
PSYCHOPHARMACOLOGY AND DRUG ABUSE RESEARCH
Both of these examples highlight the need to select subjects in a
way that will clarify, rather than obscure, possible gender by age
and hormonal status effects on drug responsivity and on drug use.
A further methodological guideline is for investigators to report
the exact statistical significance (p value) by gender, in order
to allow for subsequent combining of statistics for meta-analysis
of several clinical trials.
The example of neuroleptic-related tardive dyskinesia reminds us
to examine not only gender-related trends in therapeutic efficacy,
but also in the patterning of side effects. As detailed elsewhere
(Hamilton et al. 1984). investigators must control, or at least
describe carefully, gender-related effects on known pharmaco-
kinetic variables, e.g., body composition and serum levels. The
menstrual cycle must also be recognized consistently as a poten-
tial source of variance in psychopharmacological studies (Shader
and Harmatz 1982; Mendelson and Mello, this volume).
Finally, we must address the fact that confounding variables may
also be gender-related. Such variables may include baseline
levels of severity, placebo versus spontaneous remission rates, or
side effects related to rates of dropping-out. As mentioned ear-
lier, the complexity of people's lives must also receive recogni-
tion in psychopharmacology and drug abuse research; for example,
there are gender-related differences in cigarette smoking and
alcohol use, and these may interact with other variables pertinent
to our research. Only by greater attention to naturally occurring
patterns of drug use or abuse-- including the social ecology of
drug combination--will we begin to clarify the mechanisms for gen-
der-related effects on drug responsivity and usage (Russo 1985).
ON BARRIERS TO MOVING GENDER-RELATED METHODS INTO THE MAINSTREAM
OF DRUG RESEARCH
The scientific rationale for gender-related drug research is sim-
ply to advance knowledge and to improve the quality of research
clinically, theoretically, and empirically. From a policy point
of view, however, there are several conceptual barriers to moving
gender-related research into the mainstream (Hamilton, in press).
For example, this area is likely to be trivialized as though it
pertains only to a special "subpopulation." There is also a per-
sistent notion among basic pharmacologists that gender is such an
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obvious, almost simple-minded variable, that its study will result
only in clinical applications, as opposed to the possibility that
it will provide windows on mechanisms of drug action.
The problem with these attitudes is one of perspective. If you
speak with front-line clinicians--or with the women who actually
suffer from the perhaps needless excess of tardive dyskinesia or
with their families--even rather simple "metabolic" factors seem
less trivial. Theoretically, in fact, the study of gender-related
effects may advance a new thread of basic research, aimed at
understanding drug-hormone interactions, as one example.
Finally, we need to understand better the connections between
seemingly simple-minded variables like a e, and profound concepts
like "development," or "evolution." As the variable age is to the
concept development, so the variable gender may stand in relation
to some as yet unknown, but perhaps groundbreaking, concept in
drug research.
In summary, the use of gender comparisons is based on the long em-
pirical tradition of comparative methods in physiology and in
neuroscience (Bullock 1984). At its best, gender-comparative re-
search will both sharpen our skills in assessing the mechanisms of
drug action, and improve clinical care--not just for a single sub-
population, but for all subgroups defined by gender, age, and hor-
monal status.
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Clinical Investigations of
Drug Effects in Women
Jack H. Mendelson and Nancy K. Mello
INTRODUCTION
Because prevalence of drug abuse problems in men is generally
greater than for women in the United States (Cisin et al. 1983),
it is not surprising that most of our information about process
and outcome of drug dependence treatment has been obtained in
studies with male patients. However, recent data obtained in the
National Institute of Mental Health Epidemiologic Catchment Area
Survey revealed that drug abuse and dependence was the second most
commonly reported mental health disorder for women between the
ages of 18 and 24 (Regier et al. 1984; Eaton et al. 1984; Robins
et al. 1984; Myers et al. 1984). During 1984, 37 of the 137 pa-
tients admitted to the Drug Dependence Unit at the McLean Hospital
were women. The percentage (27 percent) of female patients admit-
ted to McLean Hospital for treatment of drug dependence is con-
sistent with a general impression that approximately one out of
four patients diagnosed as having drug abuse or dependence prob-
lems in the United States is a woman (Myers et al. 1984).
The role of gender factors in determining both safety and efficacy
of pharmacotherapy for drug dependence remains largely unexplored.
Since gender differences have been shown to influence a wide range
of pharmacologic therapies in medical practice (Vesell 1979), a
more intensive assessment of pharmacologic treatment for drug
dependence of women should be carried out.
PHARMCOLOGIC TREATMENT OF COCAINE ABUSE
In a recent review of current and experimental treatments for co-
caine abuse, Kleber and Gawin (1984) note that there are many
problems associated with criteria currently used for the diagnosis
of cocaine abuse. The importance of antecedent or consequent psy-
chiatric illness associated with cocaine abuse is not clear.
Kleber and Gawin (1984) as well as Gold (1983) have argued that
cocaine abusers may be more heterogeneous with respect to varia-
tions in drug self-administration behavior than other patients who
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request treatment for substance abuse problems. Marked hetero-
geneity has also been observed with respect to dosage, drug self-
administration patterns, presence of intercurrent illness, and
other social, biologic, and psychologic factors that appear to
have an important role in initiating and perpetuating drug abuse
(Mendelson and Mello 1982).
Our recent studies with women who have significant polydrug abuse
problems strongly suggest that the appearance of heterogeneity
among persons who are substance abusers may be accounted for, in
part, by gender differences (Lex et al. 1984; Mendelson et al.
1985; Mendelson et al., submitted for publication). Thus, target-
ed studies with women patients who have a diagnosis of cocaine
abuse, or cocaine abuse associated with alcohol abuse and depend-
ence, may assist in identifying more precisely specific factors
that may contribute to variance in biologic and behavioral indices
as well as provide a basis for more rational and therapeutic
interventions for drug abuse problems in women.
We have been able to locate only two reports of use of anti-
depressant medication for the treatment of cocaine abuse (Tennant
and Rawson 1983; Gawin and Kleber 1984). Both these studies were
"open trials" and did not utilize placebo control, double-blind
crossover procedures for determination of treatment efficacy.
However, the initial data obtained in these studies encourage more
rigorous and systematic assessment of antidepressant pharmaco-
therapy for cocaine abuse by women.
The first report of the use of the antidepressant drug desipramine
for treatment of cocaine dependence was presented by Drs. Tennant
and Rawson (1983) at the 44th Annual Scientific Meeting of the
Committee on Problems of Drug Dependence, in 1982. A summary
report of the outcome of this study was published in the National
Institute on Drug Abuse Research Monograph 43 in April, 1983
(Tennant and Rawson 1983). Drs. Tennant and Rawson stated that
the rationale for selecting desipramine for the treatment of co-
caine abuse was based upon research reported in 1961 by Dr. Julius
Axelrod, which demonstrated that amphetamines and cocaine inhibit
the reuptake of norepinephrine (Axelrod et al. 1961). Subsequent
studies showed that desipramine had the greatest degree of selec-
tivity for blockade of norepinephrine uptake by tricyclic anti-
depressants (Hollister 1978). These data suggested to Tennant and
Rawson (1983) that desipramine might be an effective drug for
treating patients with cocaine abuse.
Tennant and Rawson (1983) reported outcome data for 14 cocaine
abusers, including 4 women. Desipramine was administered on an
outpatient basis for a period of 7 to 52 days. Daily dosage of
desipramine ranged from 50 to 125 mg. Outcome data for this study
did not describe any gender differences; this was not surprising
since only 4 females out of a total of 14 patients participated in
the clinical trial. The general outcome results, however, were
encouraging since 28 percent of all patients reported total
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abstinence from cocaine use 30 to 45 days following the initiation
of the study. Tennant and Rawson (1983) cautioned that
the study must not be over-interpreted due to its non-
blind nature, the possibility of placebo effect, and
the inherent difficulty of controlling drug-dependent
research subjects. Further clarification of the role
of desipramine in the treatment of amphetamine and
cocaine dependence must await double-blind trials.
(Tennant and Rawson 1983, p. 354)
The second report describing an open pilot trial with desipramine
for the treatment of cocaine abuse was published by Gawin and
Kleber in the September 1984 issue of the Archives of General
Psychiatry (Gawin and Kleber 1984). In this study, six patients,
three males and three females, were administered desipramine in
doses of 200 mg/day and also received psychotherapy in individual
sessions once or twice weekly. Some patients also participated
in l-hour group therapy sessions and in family therapy group
meetings.
Gawin and Kleber reported that
administration of desipramine was associated with
abstinence from cocaine in all subjects so treated with
this sample, regardless of the diagnosis. It was also
associated with an anticraving effect whose time course
was similar to the delayed effects of tricyclic anti-
depressants in major depression and neuroreceptor
studies. (Gawin and Kleber 1984, p. 907)
Gawin and Kleber noted that any conclusions derived from the study
were limited because of the open nature of the trial and the lack
of double-blind placebo controls. Specific gender differences in
treatment responses and outcome were not described, although one
illustrative case report highlighted the efficacy of desipramine
pharmacotherapy for a 21-year-old female treated for cocaine free-
base smoking.
In retrospect, it is surprising that there have not been more at-
tempts to evaluate the efficacy of desipramine treatment for co-
caine abuse. Kleber and Gawin have noted findings derived from
many basic and clinical neuroscience studies that would support
the rationale for this approach (Colpaert et al. 1979; Ellinwood
1977; Fischman et al. 1976; Kosman and Unna 1968; Smith and Wesson
1980; Wesson and Smith 1977). Additional support for the poten-
tial efficacy of desipramine in the treatment of cocaine abuse may
be inferred from recent studies that have shown that tricyclic
antidepressants interact with the ionic channel moiety of acetyl-
choline receptors at the motor endplate (Eldefrawi et al. 1981;
Shaker et al. 1981) and that cocaine inhibits sodium uptake into
PC12 cells by binding to the open channel form of the receptor
(Karpen et al. 1982). In studies of the receptor-associated ionic
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channels involved in catecholamine release, Cena and his associ-
ates found that imipramine and cocaine inhibit noradrenalin re-
lease by selective inactivation of the acetylcholine receptor
ionophore (Cena et al. 1983). Cocaine and the tricyclic anti-
depressant desipramine may have a very similar mode of action on
nerve cell receptor sites and membrane ion channel function, which
regulate neuronal activity and behavior. Desipramine may act as a
pharmacologic substitute for cocaine by inhibiting norepinephrine
release via selective inactivation of the acetylcholine receptor
ionophore (Cena et al. 1983).
PHARMACOLOGIC TREATMENT OF OPIOID ABUSE AND
DEPENDENCE--NALTREXONE
During 1984, naltrexone was approved by the Food and Drug Adminis-
tration (FDA) for use as an adjunctive pharmacotherapy for the
treatment of opioid dependence. FDA approval of naltrexone fol-
lowed extensive clinical investigations that documented both the
safety and limited efficacy of naltrexone treatment for opioid-
dependent persons (Ginzberg 1984; Ginzberg and Glass 1984; Judson
et al. 1981; Julius and Renault 1976; Resnick et al. 1974; Tennant
et al. 1984; Washton et al. 1984).
A pioneering study of the effects of naltrexone on self-determined
patterns of heroin self-administration by heroin-dependent men was
initiated at the Harvard-McLean Alcohol and Drug Abuse Research
Center (Meyer et al. 1976a; Meyer et al. 1976b; Meyer and Mirin
1979). Naltrexone (75 mg/day) effectively reduced heroin use in
comparison to Glacebo controls (Meyer and Mirin 1979). The safety
of chronic naltrexone therapy was also evaluated in these studies
with particular emphasis on naltrexone effects on neuroendocrine
function (Mello et al. 1981; Mendelson et al. 1980; Ellingboe et
al. 1980).
The vast amount of data obtained concerning safety and efficacy of
naltrexone treatment has been attained in studies with men
(Ginzberg 1984; Ginzberg and Glass 1984; Judson et al. 1981;
Julius and Renault 1976: Resnick et al. 1974; Tennant et al. 1984:
Washton et al. 1984). Women were infrequently studied because the
largest number of opiate-dependent persons who received naltrexone
in protocol-based studies were primarily men with compromised
social and economic resources. In studies with more affluent per-
sons (Washton et al. 1984; Tennant et al. 1984), women represented
one-quarter to one-third of the patients treated with naltrexone,
but data obtained in these studies did not describe any gender
similarities or differences for either the safety or efficacy of
naltrexone treatment. This may be especially important since it
has been shown that opioid antagonists are potent stimulators of
both luteinizing hormone (LH) and prolactin in women (Ropert et
al. 1981; Quigley and Yen 1980). Since naltrexone has been shown
to stimulate gonadotropin secretion in males (Mendelson et al.
1979), it is likely that women may develop abnormalities of
menstrual cycle and reproductive function as a consequence of
chronic naltrexone therapy.
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Since buprenorphine is an oripavine derivative of etorphine (Lewis
1974), a potent opioid agonist, and diprenorphine, an opiate an-
tagonist (Jasinski et al. 1982; Jasinski et al. 1983; Mello and
Mendelson 1980; Mello et al. 1982), buprenorphine combines the
characteristics of both opioid agonists and antagonists. However,
unlike opiate agonists, buprenorphine does not produce severe and
protracted withdrawal signs and symptoms in man (Mello and
Mendelson 1980; Mello et al. 1982; Jasinski et al. 1978). Bupre-
norphine is also safer than opiate agonists since its antagonistic
component appears to prevent lethal overdose even at approximately
10 times the analgesic therapeutic dose (Banks 1979). This
reduces the possibility of opiate overdose deaths observed with
methadone use (Kreek 1978). Buprenorphine is equivalent to nal-
trexone in the duration of opiate antagonist action (Martin et al.
1973). A sublingual preparation of buprenorphine further enhances
its potential clinical utility for the treatment of opioid depend-
ence (Jasinski et al. 1984).
PHARMACOLOGIC TREATMENT OF OPIOID DEPENDENCE--BUPRENORPHINE
The effects of maintenance on buprenorphine, a mixed opioid
agonist-antagonist, or placebo on patterns of operant acquisition
of heroin and money were studied under double-blind conditions
(Mello and Mendelson 1980; Mello et al. 1982). Male volunteers
with histories of heroin abuse lived on a clinical research ward
for 40 days. After a 5-day drug-free period, buprenorphine or
placebo was given in gradually ascending doses (0.5 to 8 mg/day
SC) over 14 days. Subjects were maintained on 8 mg/day of bupre-
norphine for 10 days during which they could earn money ($1.50) or
heroin (7 or 13.5 mg/injection IV) by responding on a second order
schedule of reinforcement [FR 300 (Fl 1 sec:S)] for approximately
90 minutes. Buprenorphine-maintained subjects took significantly
less heroin than subjects maintained on placebo (p<.001). Of the
total amount of heroin available, buprenorphine-maintained sub-
jects took only between 2 and 31 percent, whereas placebo-main-
tained subjects took between 93 and 100 percent. One subject
maintained on a somewhat smaller dose of 4 mg/day of buprenorphine
took 55 percent of the available heroin: Tolerance to the opiate
agonist-like somatic and sedative effects of buprenorphine devel-
oped gradually. Buprenorphine maintenance did not impair operant
performance for money, Placebo subjects also showed no impairment
of operant performance for heroin and money during heroin intoxi-
cation; they titrated operant work to acquire the desired amount
of heroin and then resumed working for money. There were no sig-
nificant differences between the buprenorphine and the placebo
group in total operant points earned or total hours worked during
any phase of the study. These data indicate the effectiveness of
buprenorphine in suppressing heroin self-administration and illus-
trate the value of using direct measures of drug self-administra-
tion to evaluate new pharmacotherapies for the treatment of opiate
abuse.
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Buprenorphine also suppressed plasma luteinizing hormone (LH) and
increased prolactin levels after 12 consecutive days of ascending
dose administration in comparison to drug-free control conditions
(Mendelson et al. 1982). During a subsequent 10-day period of bu-
prenorphine maintenance at a dose of 8 mg SC, LH levels remained
suppressed and prolactin continued to be elevated. Tolerance to
buprenorphine effects on LH and prolactin levels did not occur
during chronic drug administration (Mendelson et al. 1982).
Buprenorphine-induced changes in plasma LH and prolactin after
chronic administration to human males were smaller than those ob-
served with less potent opiate agonist drugs (Mendelson et al.
1982).
We have been unable to locate any reports of buprenorphine effects
on pituitary and gonadal hormones in females. Therefore, studies
for determining safety (in addition to efficacy) of buprenorphine
pharmacotherapy for opioid-dependent women should be conducted in
the near future.
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Drug Use Patterns and
Premenstrual Dysphoria
Nancy K. Mello
The issue of how gender differences may affect drug use patterns
or the consequences of drug abuse has been largely ignored. There
appears to be an implicit assumption that information obtained
from men will be completely generalizable to women and that any
possible gender differences are of little consequence. In the
absence of data to the contrary, such attitudes are likely to
persist. Yet unless both women and men are studied, the prevalent
notion that gender differences are inconsequential cannot be
adequately tested. This essay will consider some possible impli-
cations of gender differences for our understanding of the proxi-
mal determinants and consequences of alcohol and drug abuse. The
intent is not to construct a bastian of militant feminism with a
mindless insistence on examination of women qua women--many funda-
mental biological processes are unlikely to be gender specific.
Rather the intent is to suggest some areas of investigation that
are relevant to the unique attributes of women and may present
special problems as well as special research opportunities for
studies of substance abuse.
The serious health risks associated with cigarette smoking,
alcohol and drug abuse are widely recognized, and educating women
about the health consequences of substance use has become an issue
of increasing concern. This technical review on women and drugs
initiated by the National Institute on Drug Abuse (NIDA) is an
important first step towards implementation of the recommendations
of the 1985 DHHS Task Force on Women's Health Issues concerning
substance abuse-related research. The Task Force urged that
special efforts should be made to gain knowledge about
those diseases related to alcohol and drug abuse, and
about mental illnesses of importance to women, by the
initiation of: (1) research to study depression in
women when it occurs alone or in conjunction with
alcohol or drug abuse problems; (2) studies of the
significant factors related to the onset, continuation
and cessation of smoking, drinking, and drug taking by
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women; and (3) studies of the role of the family and of
cultural attitudes in the maintenance of mental health
or the development of mental illness, as well as in the
use or misuse of alcohol, drugs, and tobacco. (Report
of the Public Health Service Task Force on Women's
Health Issues 1985, p. 81)
The Task Force report and its implications are discussed more
fully elsewhere in this monograph (Chatham, this volume).
Increased Federal attention to the health problems of women gener-
ally, and the impact of substance abuse in particular, is an en-
couraging development. In 1978, the National Institute on Alcohol
Abuse and Alcoholism (NIAAA) was among the first to sanction the
notion that alcohol abuse problems may be different in men and
women in their first research monograph, "Alcoholism and Alcohol
Abuse Among Women: Research Issues" (NIAAA 1980). In 1984, the
NIAAA sponsored a second National research conference on women and
alcohol. Since 1980, several important books on alcohol and drug
abuse problems in women have been published (Wilsnack and Beckman
1984; Kalant 1980; Sandmaier 1980; Eddy and Ford 1980). Despite
evidence of progress in reversing the longstanding tendency to
assume that women are just like men, this attitude is deeply
imbedded in our culture. Its myopic adherents appear to be
afflicted with "the Adam's Rib syndrome!" A fundamentalist's
interpretation of genesis subscribes to the belief that Adam was
"formed from the dust of the ground" and Eve from one of his
ribs. Although this is not the dominant hypothesis in contempo-
rary biomedical science, many people still behave as if this were
a guiding assumption. Calling attention to the possible impor-
tance of gender differences (except in reproductive biology) can
evoke reactions ranging from incredulity to indifference.
SUBSTANCE ABUSE: RISK AND RECURRENCE
Risk for development of substance abuse problems is influenced by
many interacting variables. The great diversity of individuals
with alcohol and drug abuse problems argues against a search for
constant etiological factors (Mello 1980; Mello 1983a). Trying to
analyze the events that maintain drug abuse behavior may be more
important than attempting to recapture the distant antecedents of
that behavior. We understand very little about the way in which
alcohol and drugs come to control behavior leading to their
repeated administration. Drinking and drug abuse problems may
develop for many reasons, but once established, there may be simi-
larities in the way abuse patterns are maintained that transcend
the specific pharmacological properties of the drug (Mello 1983b).
A once common belief was that certain drugs inevitably led to
repetitive compulsive use, motivated in part by the avoidance of
withdrawal signs and symptoms. Yet direct observations of drug
users have not supported this notion. Alcohol-dependent men
alternated between drinking and abstinence, over periods of 30 to
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60 days, despite the occurrence of withdrawal signs and symptoms
(Mello and Mendelson 1972; Mello and Mendelson 1978). Similar
cyclic patterns of alcohol self-administration were seen in rhesus
monkeys (Winger and Woods 1973). Occasional intermittent use of
heroin is also reported (Harding and Zinberg 1983). Given that
drugs are often used intermittently, it would be useful to
identify the proximal determinants of drug use and clarify the
extent to which these may differ in men and women.
Behavior is maintained by its consequences, but clinical research
has shown that the consequences of chronic alcohol and drug abuse
are considerably more complex and varied than was once believed.
Traditionally, the purported "positive" effects of intoxication
(mood elevation, rush, high, euphoria) have been considered as a
primary explanation for repeated drug abuse. Although intoxica-
tion may initially induce pleasant feeling states and diminish
feelings of anxiety and depression, chronic intoxication with
alcohol and opiates is often associated with increased anxiety and
depression (Mello 1983b). The elusive effects of chronic drug
intoxication may be reflected in microcosm in the acute effects of
drug intoxication. Biphasic changes in mood state appear to
parallel the ascending and descending phase of drug concentrations
in plasma. The transient positive changes in mood usually occur
during the rising phase of the drug concentration curve. Opiates
and cocaine may produce positive changes in feeling states within
seconds or minutes after intravenous administration. Alcohol may
produce similar effects within 30 to 90 minutes after drinking, as
the blood alcohol curve rises. But dysphoric changes in feelings
may occur after the heroin rush, after smoking cocaine paste, and
during the falling phase of the blood alcohol curve. Higher drug
doses are more likely to be associated with dysphoric changes in
subjective states. However, this generalization is qualified by
the fact that many nonpharmacological factors including expec-
tancy, drug experience, and social context modulate the perceived
consequences of intoxication (Mello 1983b; Marlatt and Rohsenow
1980).
Naive users of alcohol, opiates, and nicotine often experience
dysphoria, nausea, vomiting, dizziness, and some impairment of
concentration and thinking. Although tolerance to the adverse
effects of initial drug use may develop, another possibility is
that the initial adverse drug reactions (dysphoria, nausea,
vomiting) will persist and become an integral part of the
reinforcing properties of subsequent drug use (Mello 1983b).
To the extent that dysphoric consequences are associated with
both acute and chronic intoxication, the explanatory value of
"euphoria" is diminished. One advantage of the term "reinforce-
ment" is that it does not imply anything about the nature of the
reinforcing event. Rather reinforcement describes a functional
relationship between events and behavior. If occurrence of an
event increases behavior leading to that consequence, the event
can be defined as a reinforcer. If the removal of an event
33
increases behavior leading to it, the event can also be defined as
a reinforcer. However, if either the presentation or removal of
an event decreases behavior leading to it, the event can be
defined as a punisher (Morse and Kelleher 1977).
The maintenance of behavior by aversive or noxious events is not
unusual. There is considerable evidence that aversive consequences
such as electric shock will maintain shock self-administration
behavior in animals under certain conditions (Morse et al. 1977).
Opiate-dependent monkeys will work to produce injections of a
narcotic antagonist which, in turn, precipitate opiate abstinence
signs (Goldberg et al. 1972; Woods et al. 1975). Within this
context, the fact that the increased despondency and anxiety often
associated with chronic drug abuse are part of the complex that
maintains the drug use behavior is less surprising.
The challenge of analyzing the mercurial reinforcing effects of
drugs is further illustrated by patterns of polydrug use which
involve the concurrent use of substances with different pharmaco-
logical actions. Polydrug use of stimulants and depressants has
prompted the speculation that a change in state may be the criti-
cal reinforcing component of drug intoxication. The direction of
that change in state, up or down, may be far less important than
the change itself. Insofar as drugs are stimuli leading to some
change in subjective state, to think of drug self-administration
as a form of stimulus administration may be useful (Mello 1977;
Mello 1983b). It is possible that any drug which has definite
stimulus properties, i.e., behavioral effects for the user, is a
drug which has abuse potential (Mello 1983b).
Since expectancy is a powerful determinant of the perceived conse-
quences of intoxication, "placebo effects" may be as salient in
maintaining behavior as actual consequences (Mendelson et al.
1984). Alcoholic men recalled only the anticipated positive
effects of a drinking experience and none of the dysphoric events
during a subsequent episode of sobriety (McGuire et al. 1966;
Tamerin et al. 1970). Anticipation of a positive intoxication
experience, aided by selective recall of past intoxication, is
likely to remain an important determinant of drug use. Intoxica-
tion is a common strategy for coping with problems of all types.
However, whether or not the periodic recurrence of certain defin-
able problems reliably predicts episodes of drug use is unclear.
GENDER DIFFERENCES THAT MAY EFFECT DRUG USE PATTERNS
There is little question that the menstrual cycle uniquely differ-
entiates women of childbearing age from men. Until very recently,
the psychological concomitants of phases of the menstrual cycle
and the impact on women's health and behavior have received very
little scientific attention. The emergence of the women's libera-
tion movement in the early sixties was-accompanied by definitions
of social equality which often involved denial of sexual
differences: Attention to sexual differences was regarded as
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perniciously sexist by some. This militant extremism has gradu-
ally evolved towards the recognition that there may be important
sexual differences which have significant consequences for women's
health, a position most recently exemplified in the 1985 Task
Force on Women's Health Issues. Indeed it could be argued that
the time-honored tradition of assuming that sex-related differ-
ences are unimportant reflects a profound sexism with more poten-
tially adverse implications for women than objective examination
of these differences.
The menstrual cycle is controlled by a complex interaction between
hypothalamic, pituitary, and ovarian hormones. The synthesis and
secretion of hypothalamic and pituitary hormones is regulated by
the central nervous system and modulated by the ovarian steroid
hormones. Hypothalamic LHRH (luteinizing hormone-releasing
hormone) stimulates the production and release of pituitary
gonadotropins, LH (luteinizing hormone) and FSH (follicle-stimu-
lating hormone). Changes in the levels of pituitary gonadotropins
and ovarian steroid hormones (estrogens and progesterone) define
the successive phases of the menstrual cycle (Knobil 1980; Wilson
and Foster 1985). A schematic diagram of the hypothalamic-
pituitary-gonadal interrelationships appears in figure 1.
The menstrual cycle is usually divided into two phases which cor-
respond to the development of the ovarian follicle and ovulation
(the follicular phase) and transformation of the follicle into a
corpus luteum (the luteal phase). The onset of menses defines the
beginning of a menstrual cycle and the beginning of the follicular
phase. During the follicular phase, FSH and LH stimulate matura-
tion of the ovarian follicle and secretion of estrogen, an ovarian
steroid hormone. As the follicle matures, there is a rapid in-
crease in estrogen secretion with a surge of estrogen at midcycle.
This estrogen surge is followed by a surge in LH and FSH which
triggers ovulation, i.e., release of the ovum from the ovarian
follicle into the fallopian tube. After ovulation, the ovarian
follicle is transformed into the corpus luteum which produces
progesterone, another ovarian steroid hormone. The corpus luteum
continues to synthesize and secrete progesterone for approximately
13 days unless fertilization of the ovum and pregnancy occurs.
Increased progesterone levels prepare the uterus for implantation
of the ovum by inducing uterine glandular and vascular prolif-
eration. If pregnancy does not occur, the endometrial lining of
the uterus is sloughed off during the process of menstruation.
Demise of the corpus luteum marks the end of a menstrual cycle.
The average menstrual cycle lasts for 28 days (+ 4 days). The
follicular phase includes menses, which usually last 3 to 5 days,
and the period of follicular development, 7 to 10 days. Varia-
tions in the length of the follicular phase account for variations
in length of the normal menstrual cycle. The 2 days before and
after ovulation are usually designated as the periovulatory phase.
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FIGURE 1. A schematic diagram of the interrelationships between
the hypothalamus, the anterior pituitary, and the
ovary
NOTE: Hypothalamic secretion of LHRH Is responsible for maintaining the tonic
secretion of LH and FSH by the pituitary. Gonadotropin (LH and FSH) stimu-
lation of the ovary leads to follicular development and the secretion of
estrogens. When circulating estrogen levels reach 200 to 300 pg/ml, the
pituitary releases a surge of LH and FSH which causes the ovarian follicle
to rupture and release its ovum. The follicle Is then luteinized and
secretes progesterone. The feedback relationships between hypothalamic
LHRH, the pituitary gonadotropins, and ovarian steroid hormones are shown
by the arrows. The contribution of the central nervous system to
hypothalamic regulation is indicated by the suprahypothalamlc brain.
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The length of the luteal phase is quite consistent from cycle to
cycle, varying between 13 and 15 days. The midluteal phase, when
progesterone levels are highest, usually occurs about 8 days after
ovulation. The end of the luteal phase, 3 to 5 days before men-
struation, is commonly referred to as the premenstruum. However,
definitions of the premenstruum vary, and symptoms usually asso-
ciated with the premenstruum can occur as early as 13 days prior
to the onset of menstruation (Halbreich et al. 1982).
There is abundant clinical evidence that dysphoric mood states are
correlated with the premenstrual phases of the menstrual cycle. A
syndrome often referred to as "premenstrual tension" is character-
ized by increased anxiety, depression, tension, irritability,
sleep disturbances, lethargy, impaired concentration, headaches,
constipation, bloating, backaches, breast tenderness, weight
changes, and changes in sexual feeling and activity (Moos 1969;
Smith 1975; Steiner and Carroll 1977; Wilcoxon et al. 1976).
Although the premenstruum is most commonly associated with dys-
phoria and lability of affect, menstruation and the periovulatory
phase may also be associated with increased anxiety and depres-
sion. These symptoms may not occur in all women at every cycle,
and all are not specific to women or to the menstrual cycle
process. However, the periodic recurrence of this constellation
of symptoms in concert with phases of the menstrual cycle has been
implicated in an exacerbation of psychotic disorders, especially
depression (Smith 1975; Steiner and Carroll 1977), as well as in-
creased abuse of alcohol (Podolsky 1963; Belfer and Shader 1976;
Belfer et al. 1971). It should be emphasized that premenstrual
tension often occurs in normal women, independently of a concomi-
tant depressive disorder (Steiner et al. 1980; Haskett et al.
1980).
The existence of a premenstrual tension syndrome has been chal-
lenged on ideological as well as methodological grounds (Wilcoxon
et al. 1976; Rubinow and Roy-Byrne 1984). For example, it has
been argued that women experience discomfort because they have
been taught that they should feel premenstrual tension and anxiety
(Ruble 1977). The influence of social expectancy on reports of
menstrual-cycle-related symptoms has often been emphasized
(AuBuchon and Calhoun 1985). At the other end of the spectrum are
those who postulate that the cyclic changes in pituitary gonado-
tropins and ovarian steroid hormones, which define the phases of
the menstrual cycle, may contribute to changes in affective states
(Bardwick 1974; Steiner and Carroll 1977; Reid and Yen 1981), but
the pathophysiology of the premenstrual tension syndrome is not
understood (Vaitukaitis 1984; Rubinow and Roy-Byrne 1984). These
discrepant views point to the obvious conclusion that the pre-
menstrual tension syndrome is multiply determined, and simplistic,
single-factor explanations are unlikely to adequately account for
the syndrome. How subjective changes in feeling states are influ-
enced by expectancy or modulated by concurrent changes in pitui-
tary and gonadal hormone secretory patterns is unknown; however,
it is generally agreed that these dysphoric changes in feeling
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states are not necessarily associated with dysmenorrhea (Smith
1975; Moos 1969).
An association between mood fluctuations and menstrual cycle
phases has been consistently established despite a wide diversity
of methods and subjects. One recent study examined changes in
mood and physical symptoms in women in treatment for severe pre-
menstrual tension and compared them with women with a history of
premenstrual tension and with asymptomatic women (Sanders et al.
1983). Phases of the menstrual cycle were defined by measurement
of pituitary and gonadal hormones. All women showed similar
changes in mood and physical states as a function of cycle phase.
Feelings of well-being were greatest during the late follicular
phase and declined during the luteal phase. Self-ratings of de-
pression, irritability, and physical complaints began to increase
during the early luteal phase and were maximal at the pre-
menstruum. The magnitude of these changes was greatest in the
groups that reported premenstrual tension. Women in treatment for
premenstrual tension reported intense negative experiences often
beginning early in the luteal phase and increasing significantly
at the premenstruum (Sanders et al. 1983).
Since some women do experience anxiety and dysphoria in associa-
tion with the late luteal (premenstrual) phase of the menstrual
cycle, it is tempting to postulate that these may be accompanied
by various forms of self-medication behavior including increased
use and abuse of alcohol and other drugs. A schematic diagram
illustrating this hypothesis appears in figure 2. Recurrent men-
strual cycles are shown at the top of the figure, and the onset of
premenstrual dysphoria is shown as a dark bar in the second row.
The hypothesis that menstrual cycle mood changes may be associated
with increased alcohol and drug use is shown in the third and
fourth rows.
ALCOHOL USE AND MENSTRUAL CYCLE PHASE
The evidence relating to this hypothesis is somewhat sparse, but
provocative. Podolsky (1963) was one of the first to state this
hypothesis explicitly on the basis of clinical observations of
seven female patients with alcohol problems. Each patient re-
ported that she drank most heavily during the premenstrual period,
and each patient suffered from severe premenstrual tension.
Podolsky (1963) concluded that
in general, such women drink in order to alleviate the
symptoms of premenstrual tension. The tempo of drink-
ing is increased during the premenstruum. Alcohol is
utilized partly to relieve tension, but for the most
part to allow acting out and verbalization of passivity
demands. (Podolsky 1963, p. 818)
The clinical impression that alcohol use is related to pre-
menstrual tension was confirmed by Belfer and coworkers in 1971.
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FIGURE 2. Schematic diagram of possible association between men-
strual cycle, mood changes, and drug/alcohol intake
Self-reports of the relation of premenstrual tension and/or meno-
pause to drinking patterns were obtained from 34 alcoholic women
and 10 nonalcoholic women who accompanied their alcoholic husbands
to an alcohol clinic. Over half of the alcoholic women related
drinking to the menstrual cycle, especially to the premenstrual
period. Belfer and coworkers (1971) commented that
this association was made in the absence of obvious
disturbances in sexual or menstrual function and in
lieu of any difference in the scores of women who
experienced maximal versus minimal task interference,
physical discomfort or psychological discomfort during
their menstrual cycle. (Belfer et al. 1971, p. 543)
MARIJUANA USE AND MENSTRUAL CYCLE PHASE
Marijuana is probably the most frequently used illicit drug in
this country today (Clayton 1984) and marijuana use among women
appears to be increasing (Abelson et al. 1977; Smart 1983). The
possible effects of chronic marijuana use on pulmonary and
39
reproductive function is an issue of continuing concern (Fehr and
Kalant 1983; Marijuana and Health 1982; Braude and Ludford 1984).
In the context of a series of studies designed to examine mari-
juana effects on female reproductive function and behavior, we
examined the extent to which marijuana acquisition and use
patterns covaried with specific phases of the menstrual cycle
(Mello and Mendelson 1985). Twenty-one young women (average age
26.7 ± 1.15 years) who reported smoking marijuana for an average
of 8.1 (± 0.89) years gave informed consent for participation in
clinical research studies. Each woman was in good health as
determined by clinical and laboratory examinations. Women were
studied in groups of three or four and lived on a clinical re-
search ward for 35 days. A 7-day drug-free baseline was followed
by 21 days of marijuana availability and a postmarijuana drug-free
period of 7 days. Operant techniques were used to provide an
objective and quantitative measure of performance for two alterna-
tive reinforcers, marijuana and money. Women could work for money
throughout the study and for marijuana during the period of
marijuana availability by pressing a button on a simple operant
manipulandum. Women could earn either one marijuana cigarette
(1 gm containing approximately 1.83 percent delta-9-THC) or 50
cents by 30 minutes of operant work on a second-order FR 300
(FI 1 sec: [S]) schedule of reinforcement. A fixed ratio (FR) of
300 responses on the fixed interval (FI) 1-second component of the
schedule was required to earn a single purchase point. The FI 1-
second schedule specified that only the first response after
1 second had elapsed was recorded as an effective response by the
programming circuitry. Approximately 5 minutes of operant per-
formance was required to earn 300 effective responses, or one
purchase point on the FI 1-second schedule. Six purchase points
were required to buy one marijuana cigarette or to earn 50 cents
upon completion of the study.
Since subjects were studied in groups, scheduling admissions to
coincide with any specific phase of the menstrual cycle was not
possible. However, the period of marijuana availability extended
over most of a complete menstrual cycle in 7 women and coincided
with the premenstruum, defined as 3 days immediately before
menstruation, in 15 women. Five of these fifteen women increased
marijuana use during the premenstruum; five women decreased mari-
juana use during the premenstruum; and five women showed no change
in marijuana use during the premenstruum.
Examination of scores on the Premenstrual Assessment Form (PAF)
(Halbreich et al. 1982) showed a striking concordance between
premenstrual dysphoria and marijuana use during the premenstruum.
Women who increased marijuana use at the premenstruum reported
significantly greater depression, anxiety, mood lability, anger,
irritability, and impaired social functioning (p<.O5) than women
whose marijuana use decreased or stayed the same. Severity of
premenstrual dysphoria appeared to be more important in differ-
entiating the three groups of women than physical discomfort
associated with the premenstruum. Although women who increased
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marijuana use reported greater physical discomfort, pain, nausea,
dizziness, and general malaise than the other two groups, with the
exception of signs of water retention, these differences were not
statistically significant. These data suggest that the dysphoric
component of premenstrual tension is probably more closely asso-
ciated with increased drug use than dysmenorrhea (Mello and
Mendelson 1985).
An association between increased use of marijuana and alcohol and
premenstrual dysphoria lends support to the notion that depression
and anxiety associated with the premenstruum may be one proximal
determinant of episodic increases in drug use by women. However,
the experience of premenstrual dysphoria appears to be a critical
factor, since recent studies indicate that drug use does not co-
vary with menstrual cycle phase in women who do not report pre-
menstrual dysphoria. Daily marijuana use did not covary with
menstrual cycle phase in 30 women who reported no significant
increase in Moos Menstrual Distress Questionnaire (MDQ) factors
reflecting negative affect, decreased concentration, behavior
change, or arousal (Griffin et al. 1985). Women completed daily
diaries reporting drug use and MDQ (Form T) scores for three
consecutive menstrual cycles, and 2,715 of a possible 2,741
diaries were returned. The group reported smoking an average of
1.4 (± 2.0) marijuana cigarettes per day, and individuals smoked
between 7.3 (± 3.8) and 0.1 (± 0.4) marijuana cigarettes per day
(Griffin et al. 1985). Both marijuana and alcohol use increased
on weekends, and day of the week predicted drug use more reliably
than any other variable in this sample. Neither unusual life
events nor sexual activity were associated with concurrent alcohol
and marijuana use (Lex et al. 1985).
The lack of significant variation of these MDQ factors across
phases of the menstrual cycle was surprising since these female
marijuana users were similar to the Moos normative sample in age,
education, and menstrual cycle characteristics (Moos 1969).
However, Moos' normative sample differed from women studied by
Griffin and coworkers (1985) in that 9.7 percent were pregnant
during standardization of the MDQ and over half were currently
using a contraceptive pill.
DO DRUG EFFECTS DIFFER AT DIFFERENT PHASES OF THE MENSTRUAL CYCLE?
An issue related to the question of whether or not menstrual cycle
phases affect drug self-administration is whether drug effects
remain constant across the menstrual cycle. The literature con-
cerning changes in the effects of alcohol in women at different
phases of the menstrual cycle is conflicting and inconsistent
(Mello 1980). According to reports in 1976, women develop higher
blood alcohol levels at the premenstruum than during menstruation
or at midcycle after equivalent doses of alcohol (Jones and Jones
1976a; Jones and Jones 1976b). Women absorbed alcohol more rapid-
ly and developed significantly higher blood alcohol levels at the
premenstrual period (80 mg/dl) than during menstruation or cycle
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days 13 through 18 (64 and 68 mg/dl). Three women were studied
daily throughout a single menstrual cycle and given a moderate
dose of alcohol (0.66 ml/kg) at the same time each morning. There
was considerable variation in blood alcohol levels, but the high-
est peak blood alcohol levels occurred during the premenstruum and
at the periovulatory phase of the menstrual cycle (Jones and Jones
1976b). The investigators hypothesized that these data might be
related to more rapid alcohol absorption (Jones and Jones 1976a;
Jones and Jones 1976b). These data were surprising since in-
creased water retention associated with the premenstruum would be
more likely to result in lower blood alcohol levels after a fixed
alcohol dose than at other times during the menstrual cycle. The
degree of water retention in relation to the total body water-
lipid pool would determine alcohol dilution in body water
compartments.
Recent clinical studies have not confirmed reports that blood
alcohol levels vary with menstrual cycle phase. Peak blood
alcohol levels did not differ at the premenstruum, menstruation,
and cycle days 12 to 15 in 9 women given sufficient alcohol to
produce peak blood alcohol levels of 103 mg/dl (Hay et al. 1984).
One limitation of these clinical studies was that menstrual cycle
phase was defined by calendar estimates and subsequent verifica-
tion of predicted cycle phase was not reported. Changes in
pituitary and gonadal hormone levels that define each menstrual
cycle phase were not measured. A number of variables which might
influence alcohol absorption and metabolism, such as drinking
frequency, recency of alcohol consumption, other drug use, nutri-
tional status, and hours of fasting, usually were not reported,
and only a relatively low dose of alcohol was studied.
We reexamined the question of whether or not blood alcohol levels
after a standard dose of alcohol vary as a function of menstrual
cycle phase in female macaque monkeys (Mello et al. 1984).
Monkeys were studied at four phases of the menstrual cycle: the
premenstruum, menstruation, the periovulatory phase, and the mid-
luteal phase. Calendar estimates of menstrual cycle phase were
confirmed by radioimmunoassay of LH and estradiol. Ascending and
peak blood alcohol levels after low (1.5 g/kg), moderate (2.5
g/kg), and high (3.5 g/kg) doses of alcohol were measured. The
average peak blood alcohol levels after nasogastric intubation of
low, moderate, and high doses of alcohol averaged 139 mg/dl, 238
mg/dl, and 335 mg/dl. There were no differences in peak blood
alcohol levels at the premenstruum, menstruation, the peri-
ovulatory phase, or the midluteal phase of the menstrual cycle
after a standard dose of alcohol. The only difference as a func-
tion of menstrual cycle phase was the rate of increase in blood
alcohol curve after a low dose of alcohol. Blood alcohol levels
were significantly higher 30 minutes after alcohol administration
during the premenstruum than during menstruation or the midluteal
phase (p<0.02). However, at higher alcohol doses, no significant
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differences were observed in the rate of increase in blood alcohol
levels as a function of menstrual cycle phase (Mello et al. 1984).
Recent studies of the acute effects of marijuana on subjective
mood reports and pulse rate also showed no differences as a func-
tion of menstrual cycle phase (Lex et al. 1984). Twenty-eight
women volunteered to live on a clinical research ward for 4 con-
secutive days. On the second and fourth days following admission,
women were given marijuana (one 1-gm cigarette containing approxi-
mately 1.8 percent delta-9-THC) or marijuana placebo under double-
blind conditions. Ten women were studied during the follicular
phase of the menstrual cycle and nine during the luteal phase.
While five subjects were studied during the ovulatory phase of the
menstrual cycle, the brief duration of the periovulatory phase
precluded their serving as their own controls, so a separate con-
trol group of four women were compared. Marijuana produced sig-
nificant increases in ratings of intoxication within 15 minutes
after smoking, whereas placebo marijuana cigarettes did not. How-
ever, there were no significant differences as a function of
menstrual cycle phase in subjective level of intoxication or the
time course or degree of elevation in pulse rate following mari-
juana. Marijuana did not alter factor scores on the POMS (Profile
of Mood States) for friendliness, anger, fatigue, depression,
tension, vigor, or elation. However, the confusion score (which
includes feeling more confused, unable to concentrate, muddled,
bewildered, forgetful, uncertain about things, and unable to be
efficient) did increase after marijuana but not after placebo
smoking. Confusion was somewhat more pronounced in subjects
studied during the follicular phase (Lex et al. 1984).
In contrast to the relative lack of effects of menstrual cycle
phase on subjective and physiological reactions to marijuana,
there was a significant influence of history of marijuana smoking.
Intermittent marijuana smokers (five or less times each week) had
significantly higher pulse rates, subjective levels of intoxica-
tion, and POMS confusion scores than subjects with a past history
of regular marijuana use defined as six or more times each week.
Marijuana-induced changes in pulse rate, intoxication, and confu-
sion persisted longer in subjects with a history of intermittent
marijuana smoking (Lex et al. 1984).
These studies suggest that the effects of alcohol and marijuana
remain relatively constant across the menstrual cycle. Since
there appears to be no compelling evidence that alcohol and drug
effects become more salient at any particular menstrual cycle
phase, any changes in drug use which are consistently correlated
with a specific phase of the menstrual cycle probably cannot be
attributed to cycle-related changes in drug effects.
SEX DIFFERENCES AND ALCOHOL EFFECTS
Alcohol is unique among abused drugs in that it is distributed
throughout body water and its concentration is affected by body
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habitus (Kalant 1971). Men and women differ in total body water,
and there are reports that women develop higher blood alcohol lev-
els than men after an equivalent dose of alcohol (Jones and Jones
1976a; Jones and Jones 1976b; Dubowski 1976). Acute alcohol doses
of 0.33, 0.66, and 1.32 ml/kg each produced higher blood alcohol
levels in women than in male controls (Jones and Jones 1976a;
Jones and Jones 1976b). These findings were interpreted to indi-
cate that since women have less water per body unit than males,
and since alcohol is distributed throughout the body water, the
same dose of alcohol should result in higher peak blood alcohol
levels in females than in males. However, this view has recently
been challenged in studies of the acute effects of alcohol in men
and women when data were adjusted statistically for total body
water, estimated anthropometrically, or measured directly by 3H-
water dilution (Sutker et al. 1983; Marshall et al. 1983). The
most recent data illustrate the differential effects of the method
used to calculate the alcohol dose (Goist and Sutker 1985). Blood
alcohol levels in 12 men and 12 women (tested at the premenstrual
phase of the menstrual cycle) were compared following acute alco-
hol administration. When alcohol doses were equated for body
weight, women reached significantly higher peak blood alcohol con-
centrations than men. However, when equivalent alcohol doses were
based on total body water, there were no significant sex differ-
ences. Self-reported levels of intoxication at peak blood alcohol
levels did not differ as a function of either alcohol dose deter-
mination or sex (Goist and Sutker 1985).
Detailed comparisons of the effects of other drugs as a function
of sex are not currently available. However, it seems unlikely
that the effects of drugs administered intravenously or via inha-
lation would differ appreciably as a function of sex.
CONCLUSIONS
The effects of drugs do not appear to differ as a function of
phase of the menstrual cycle. In women who do not experience pre-
menstrual dysphoria, there appears to be no consistent relation-
ship between drug use and menstrual cycle phase. However, there
is some evidence that women who do have premenstrual dysphoria may
increase alcohol and/or marijuana use at the premenstruum. These
data suggest that premenstrual dysphoria may be one proximal de-
terminant of increased drug use by women. Insofar as the periodic
recurrence of premenstrual dysphoria covaries with changes in drug
use, this may be one factor that differentiates drug use patterns
in men and women. Further studies will be necessary to evaluate
this hypothesis and examine the generality of the apparent co-
variance between alcohol and drug use and premenstrual dysphoria.
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Gender Dimorphism in Brain
Michael Baum
The classic research of Jost (1950) and, more recently, of Wilson
et al. (1981) established that androgen, secreted by the mammalian
testes during fetal development, plays a crucial role in organiz-
ing the internal and external genital structures that are charac-
teristic of the male. In the absence of this androgenic stimula-
tion, individuals of either genetic sex develop phenotypically
feminine internal and external genitalia. Knowing these facts,
Young and his coworkers (Phoenix et al. 1959) provided the first
indirect evidence that perinatal exposure of the male to testicu-
lar hormones permanently alters the structure of the mammalian
brain. Working with guinea pigs, these workers found that pre-
natal administration of testosterone (T) to pregnant animals
caused two types of change in the reproductive behavior of the fe-
male offspring. First, it defeminized their behavior, i.e., re-
duced their capacity to display feminine coital behaviors after
adult treatment with ovarian steroids. Second, it masculinized
their behavior, i.e., augmented their ability to display masculine
coital patterns of behavior after adult treatment with T. Subse-
quently, these findings were repeated and extended in a wide vari-
ety of mammalian species (Baum 1979).
Further research, carried out in several nonprimate mammalian spe-
cies, showed that perinatal exposure to testicular androgens also
defeminizes the ability of the hypothalamic-pituitary axis to me-
diate estrogen-induced surges in luteinizing hormone (LH), which
is characteristic of females around the time of ovulation (Neill
1972).
Although most investigators assumed that both these behavioral and
neuroendocrine consequences of perinatal androgen exposure re-
flected a permanent, structural change in the CNS, it was only in
1971 that the first direct demonstration of such a structural
change was published. Raisman and Field (1971) used electron mi-
croscopy to analyze synaptic connectivity in the dorso-lateral
portion of the rat preoptic area (POA). They reported that, in
females, preoptic dendrites receive a higher proportion of affer-
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ent inputs onto dendritic spines than in males. Furthermore, neo-
natal treatment with T created the male phenotype in genetic fe-
males (Raisman and Field 1973).
This first finding of a sex dimorphism in neural connectivitywas
followed by a report (Nottebohm and Arnold 1976) that the fore-
brain nuclei that control singing in song birds are larger in
males (which typically sing) than in females (which sing consider-
ably less than males). These first efforts laid the groundwork
for numerous subsequent studies that have firmly established that,
in several vertebrate classes, testicular hormones act in the male
during species-specific, critical periods of development to alter
the morphology of certain brain regions.
Raisman and Field (1971; 1973) originally directed their attention
to the rat preoptic area (POA) because earlier research had
implicated this area in the control of both reproductive behavior
and the estrogenic regulation of LH secretion, two functions that
were known to be sexually dimorphic. These workers used a tedi-
ous, quantitative analysis of synaptic connectivity to demonstrate
a neural dimorphism. More recent work with the rat (Gorski et al.
1978), and subsequently with the guinea pig (Hines et al. 1985),
gerbil (Commins and Yahr 1984a), and human (Swaab and Fliers 1985)
has shown that nuclei exist in the male POA that are significantly
larger, i.e., contain more neurons, than in the female. Along a
similar line, my coworkers and I (Tobet et al., in press) recently
found that, in the male ferret, a bilateral nucleus exists in the
dorsal portion of the POA/anterior hypothalamus (POA/AH) which is
not present in females (figure 1). This dorsal nucleus (dn) of
the POA/AH consists primarily of neurons with large cell bodies.
The somal areas of these neurons increased significantly in
response to adult exposure to T or either of the two primary neur-
al metabolites of T, estradiol (E) and dihydrotestosterone (DHT),
but not to progesterone (Tobet et al., in press).
Adult exposure of gonadectomized female ferrets to these gonadal
steroids failed to organize a male-like dnPOA/AH, nor did these
treatments affect somal areas in cells located in the dorsal por-
tion of the female POA/AH. Whereas adult exposure to sex steroids
failed to create a dnPOA/AH in female ferrets, prenatal exposure
to T, achieved by administerin T pellets to pregnant ferrets over
the last 11 days of gestation (total gestation is 42 days), cre-
ated a male-like dnPOA/AH in genetic females. Neonatal castration
of male ferrets failed to block the normal development of a
dnPOA/AH.
Taken together, these data show that the final quarter of gesta-
tion constitutes the critical period for the formation of this
sexually dimorphic structure in the male ferret diencephalon.
A large body of literature (Callard et al. 1984) shows that, dur-
ing perinatal development, androgen is readily converted into
estrogen in subcortical brain regions of all vertebrate species
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FIGURE 1. Photomicrographs of sequential 60-micron-thick coronal
sections through the preoptic/anterior hypothalamic
area (POA/AH) of one gonadectomized adult female (A,
B, and C) and one male (D, E, and F) ferret
NOTE: Sections were stained with thionin. One bilateral nucleus can be seen in
the ventral POA/AH of males and females (straight arrows), whereas in males
a second more dorsal bilateral nucleus is also discernible (curved
arrows). Magnification approx. 30x. AC- anterior commissure: OC- optic
chiasm; V- third ventricle; acn- suprachiasmatic nucleus.
studied to date. The ferret is no exception to this rule. High
levels of aromatase activity (the enzyme complex responsible for
conversion of androgen to estrogen) are present in the AH/POA,
hypothalamus, and temporal lobe of perinatal ferrets of both sexes
(Tobet et al. 1985). Also, neural receptors for estrogen were
isolated in these same brain regions 5 days prior to birth (ear-
lier ages were not assessed), suggesting that the intraneuronal
receptors for E are available prenatally to mediate biological
actions of any estrogen present (Vito et al. 1985). These obser-
vations, together with the finding (Erskine and Baum 1982) that
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plasma concentrations of T are significantly higher in males than
in female ferrets prenatally, led us to ask whether the ability of
T to create a dnPOA/AH in ferrets when given experimentally to fe-
tal females, or when secreted endogenously in fetal males, depends
on the formation and action of estrogenic metabolites of this
testicular androgen. The answer is, quite unambiguously, yes.
Tobet (1985) found that administration of the steroid, 1,4,6-an-
drostatriene-3,17-dione (ATD) to pregnant ferrets almost complete-
ly inhibited the synthesis of estrogen from androgenic precursor
in fetal hypothalamus. Thus, adding ATD administration to other
methods for eliminating estrogens from the fetal environment of
the male ferret may block development of the dnPOA/AH. Male fer-
rets whose mothers were ovariectomized and given progesterone (to
sustain pregnancy) plus ATD over days 30 to 41 of gestation lacked
a dnPOA/AH in adulthood. Prenatal administration of a high dosage
of E, together with ATD, reversed this inhibition, and promoted
the development of a dnPOA/AH. Furthermore, prenatal exposure to
an androgen receptor antagonist, flutamide, failed to attenuate
the development of a dnPOA/AH in other males.
These findings show that local neural formation of E from T during
embryonic development is required for the normal development of
one sexually dimorphic feature of the dorsal POA/AH. In the rat
the medial nucleus of the POA/AH is larger in males than in fe-
males (Gorski et al. 1978), and some evidence suggests that this
size difference results from the action of estrogen perinatally in
the male (Dohler et al. 1984). Although more species need to be
studied, prior to proposing a universal role for estrogenic metab-
olites of T in creating CNS sex dimorphisms, strong data for two
mammalian orders, rodentia (rat) and carnivora (ferret), point in
this direction.
To date, there is only limited evidence linking the existence of
morphologic dimorphisms of the POA/AH to sex differences in neuro-
endocrine or behavioral function. The best example of such a link
exists in the gerbil, where lesions of the sexually dimorphic nuc-
leus of the POA/AH in males caused severe deficits in scent mark-
ing and masculine coital behaviors (Commins and Yahr 1984b). To
date, such studies have not been successful in the rat (Arendash
and Gorski 1983). That is, although workers have long known that
the rat POA contributes to the control of both masculine and femi-
nine sexual behavior in males and females? respectively, and to
the control of LH secretion in females, discrete manipulations of
the sexually dimorphic area of the POA/AH have not caused consis-
tent changes in any of these functions.
There is. however, suggestive evidence in the ferret that the es-
trogen-dependent dnPOA/AH may contribute to the normal process of
coital masculinization in the male. Behavioral studies were car-
ried out using the same ferrets that had been used in our anatom-
ical study (Tobet 1985). All animals were castrated on postnatal
day 5, and later in adulthood were given T propionate daily, prior
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to being tested with sexually receptive females. Compared with a
group of control males that were castrated on postnatal day 114,
males that were castrated on postnatal day 5, and whose mothers
were sham-operated (ovariectomized) and sham-implanted (progester-
one plus ATD), displayed significantly lower levels of neck grip,
mount, and pelvic thrusting behavior (coital behaviors displayed
by the male ferret). However, males derived from mothers that had
been ovariectomized and given progesterone plus ATD over gesta-
tional days 30 to 41 displayed even lower levels of these mascu-
line coital behaviors than either control males or males whose
mothers had received flutamide during gestation. Thus, we hypo-
thesize that prenatal exposure to estrogenic metabolites of T
leads to the development in males of a dnPOA/AH, which in turn
promotes the sensitivity of the neonatal CNS to the behavioral,
masculinizing action of T itself.
At present, no evidence exists showing whether, in humans, pre-
natal exposure of the developing male POA to estrogen promotes the
development of the recently described sexual dimorphism of the
POA/AH (Swaab and Fliers 1985). A recent study (Ehrhardt et al.
1985) has, however, shown that prenatal exposure of women to the
synthetic estrogen, diethylstilbestrol (which in past years was
given to pregnant mothers as an anti-abortion agent) did cause a
small, yet statistically significant, increment in the incidence
of homo- or bisexual orientation, as compared with either sibling
or clinical control groups. Much more work remains to be carried
out on both the behavioral and anatomical facets of human sexual
differentiation. However, the available evidence is in general
agreement with the results of experiments conducted using several
different nonhuman mammalian species, including the ferret.
How do the above data concerning hormonally determined sex di-
morphisms in brain morphology as well as in behavioral potential
relate to the issue of gender and drug abuse? They may relate in
at least two ways. First, the response of male and female pa-
tients to a therapeutic drug or to a drug of abuse may differ as a
result of sexually dimorphic differences in brain structure. To
date, most research along this line has been limited to elucidat-
ing sex differences that can be attributed to the action of sex
steroids (ovarian steroids in the female/testicular steroids in
the male) in either the liver (Gustafsson et al. 1980) or the
brain (Decker et al. 1982). However, in neither animal models nor
in man has much attention been paid to the possible contribution
of sexually dimorphic neural structures or connectivity per se as
keys to gender differences in drug action.
As more information becomes available concerning the existence of
sex dimorphisms in brain structure, I expect more studies will be
directed specifically to assessing possible consequences for drug
action. A second possible interaction between drugs and gender
dimorphisms in the brain concerns the possible effect of drugs
consumed by the mother on the development of normal sex dimorph-
isms in brain structures. To my knowledge, nobody has shown di-
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rectly that prenatal or perinatal exposure to any drug can influ-
ence the development of sexually dimorphic neuronal structures.
However, much data concerning the effects of several drugs of
abuse on neuroendocrine and behavioral parameters strongly sug-
gests that perinatal drug exposure may ultimately affect behavior
by altering the development of sexually dimorphic neural features.
A brief, selective review follows of studies in which perinatal
exposure to drugs of abuse affected neuroendocrine function or be-
havioral development in animals. Administration of tetrahydrocan-
nabinol to pregnant mice caused a significant reduction in plasma
T in fetal male offspring; this deficit in T was associated with a
long-term reduction in masculine coital ability (Dalterio and
Bartke 1978; Dalterio and Bartke 1981). Similar reductions in fe-
tal testicular secretion of T were observed in male rats born of
mothers given phenobarbitol at the end of gestation (Gupta et al.
1982). Neonatal administration of pentobarbitol to male hamsters
caused permanent deficits in masculine coital capacity (Clemens et
al. 1979). Likewise, administration of morphine to pregnant rats
late in gestation caused reductions in plasma T in fetal males
that were associated with long-term deficits in masculine coital
potential (Ward et al. 1983). By contrast, no such behavioral ef-
fect was obtained in male offspring derived from rats in which
morphine treatment was stopped just prior to the onset of the ges-
tational age of sexual differentiation, e.g., gestational day 18
(Vathy et al. 1985). In another study (Lumia et al. 1985) chronic
ingestion of ethyl alcohol by pregnant rats caused significant
increments in the ability of male offspring to display feminine
sexual behavior in response to adult treatment with ovarian hor-
mones (i.e., ethanol attenuated the normal process of coital de-
feminization) without affecting masculine coital potential.
Similar effects were recently reported in the male offspring of
pregnant rats treated with nicotine (Rodriguez-Sierra 1985).
None of these reported effects of various drugs of abuse on the
reproductive behavioral capacity of offspring have as yet been
linked directly to changes in the brain structure. In several in-
stances, however, the effects of fetal exposure of drugs of abuse
on later behavior have been linked, particularly in the male, to
reductions in circulating levels of T. Such results, along with
the knowledge that prenatal exposure either to T itself or to es-
trogenic metabolites of T may contribute importantly to brain sex-
ual differentiation in males of several mammalian orders, raises
the question of whether drug abuse in pregnant women may disrupt
the normal course of brain sexual differentiation in their male
fetuses. More basic studies on the hormonal regulation of brain
and behavioral sex determination, coupled with studies on the pos-
sible effects of perinatal drug exposure on this process, are
needed to answer this question.
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Drugs and Drug Interactions in
the Elderly Woman
Monique C. Braude
Although the elderly are commonly assumed not to be users of il-
licit drugs, they are generally recognized as having a high level
of use of legal drugs. In fact, when speaking of the elderly, it
seems more appropriate to speak of drug misuse than of drug abuse
(Glantz 1982). To avoid confusion, definitions of the terms drug
misuse and drug abuse will be those adopted by the Federal
Strategy Council on Drug Abuse in 1979.
Drug abuse is the nontherapeutic use of any psychoactive sub-
stance, including alcohol, in such a manner as to adversely affect
some aspects of the user's life. The substance may be obtained
from any number of sources: by prescription, from a friend, over-
the-counter, or through the illicit market. The use pattern may
be occasional or habitual. Drug misuse is the inappropriate use
of drugs intended for therapeutic purposes. This includes inap-
propriate prescribing or use of drugs resulting from inadequate
knowledge of the drug's effects, by either the physician or the
patient; it also includes self-medication by the patient in a
manner inconsistent with the label information.
One difference between men's and women's use/misuse is owing to a
higher proportion of women (60 percent) among the U.S. population
aged 65 years and older. Because of the longer life expectancy of
women, the problems of the elderly are increasingly those of
women. Future growth of the older population is expected to be
substantial and, by the year 2000, the Census Bureau projects a
population of 19 million older women versus 12.7 million older
men. In spite of this fact, research has failed to explore ade-
quately the unique health problems of the older woman.
RISK OF ADVERSE EFFECTS DUE TO DRUG INTERACTIONS
Of major concern is the elderly woman at especially high risk for
harmful effects from drug interactions. In Hecht's review of
medicine and tie elderly (1983), the author pointed out the
following facts. The elderly--those 65 and over--constitute at
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present about 11 percent of the total population, yet they take
about 25 percent of all drugs dispensed in the United States, both
prescription and over-the-counter (OTC). It is the rare older
patient who needs only one or two prescription drugs. For most,
polypharmacy is the rule rather than the exception. A University
of Florida College of Pharmacy survey reported, in 1980, that
elderly patients took an average of eight different drugs a
month. Other studies have shown that older patients may be get-
ting as many as 14 to 18 different drugs in the course of a year.
Nursing home patients have been reported to take as many as 20 to
30 drugs.
The reason the elderly take so many drugs is not hard to under-
stand. They are more likely than other age groups to have one or
more chronic illnesses, including heart disease, high blood pres-
sure, diabetes and arthritis. Few such diseases can be treated
with just one drug. Medication for chronic ills usually must be
taken over long periods, frequently for the rest of the patient's
life.
Elderly women have been prescribed drugs such as estrogens to
replace diminished hormones after menopause and to prevent later
years' osteoporosis. They also use sedatives, hypnotics, anti-
anxiety drugs, antihypertensive medication, vitamins, analgesics,
diuretics, laxatives, and tranquilizers at a rate of two and a
half times that of elderly men.
The very fact that the elderly must take so many medications in-
creases their chance of experiencing adverse reactions--a chance
three times greater than that of the younger patient. Such reac-
tions may be severe enough to require hospitalization. The reac-
tions elderly patients may experience include stupor, confusion or
paradoxical overstimulation from sedatives, intestinal bleeding
from aspirin, lowered blood pressure from antipsychotics such as
chlorpromazine, and fainting following use of antidepressants,
diuretics, sedatives, tranquilizers, and some high blood pressure
medications.
Taking so many drugs also increases the potential for harmful drug
interactions. One drug can alter the effect of another, for
instance, by speeding up or slowing down its metabolism in the
liver, so that two similar drugs taken together may produce an
effect that is greater than expected, or the drugs may counteract
one another. Women, according to Hamilton and Parry (1983), and
as supported by data from the Drug Abuse Warning Network (DAWN),
have more adverse drug reactions than men and, especially after
menopause, may be more vulnerable to tardive dyskinesia, a dis-
order associated with use of psychoactive drugs.
The young as well as the old patient can experience adverse drug
reactions, but the problem is compounded in the elderly by the
very process of growing old. With age, there are physiological
changes that can affect the way in which drugs behave in the body
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(Barry, this volume). In addition, such factors as diet, alcohol
consumption, disease, weather conditions (such as high heat and
humidity), malnutrition, and even bed rest can alter the movement
of drugs through the body.
The potentiation of psychoactive drug effects by alcohol may rep-
resent an additional danger for older women. Although generally
less recognized than for men, use of alcohol by older women to
combat depression or feelings of inadequacy or loneliness exists,
and can interfere with the drugs that they are taking for medical
purposes. As the environmental stresses (such as loss of spouse,
family and friends, income, employment, decreased physical beauty,
mobility, health, stamina, valued roles at home and in the neigh-
borhood, independence, self-esteem) increase in later years, women
whose habitual coping responses to stress involved drinking or
drug taking may be particularly vulnerable in old age. Most of
the psychoactive drugs taken by the elderly woman to combat
depression, for instance, are potentiated by alcohol, resulting in
overdose incidents.
CHANGES IN DRUG DISPOSITION WITH AGE
The elderly woman may also be at risk due to changes in drug dis-
position, which may be the result of changes in absorption, dis-
tribution, metabolism, or elimination occurring with age. Drugs
usually enter the body by mouth or by injection. How well drugs
will produce their effect depends first on how well they are ab-
sorbed. While there is no clear evidence that age alone affects
absorption, it has been suggested that decreased absorption might
occur as a result of physiological changes such as decreased gas-
tric acidity, or a reduction in peristaltic activity that changes
the time it takes food to leave the stomach, or a decreased
intestinal blood flow.
Where age does make a difference is in drug distribution, the pro-
cess by which drugs are delivered to various sites in the body.
Drug distribution in the elderly is altered in part because of
changes in the body's composition. The total body water and lean
body mass--essentially muscle and bone--decrease, while the pro-
portion of fat increases, even though there is no increase in
total weight. This means that drugs normally distributed in lean
body tissue, such as digoxin, will end up at higher concentrations
in the bloodstream. On the other hand, barbiturates (Nembutal and
others), phenothiazines (Thorazine and others), and diazepam
(Valium) are stored in fatty tissue. The increased fat in the
elderly can serve as a reservoir for these drugs and prolong their
"working" time.
Drug distribution can also be altered by age-related changes.
Plasma proteins in the blood aid in transporting many drugs from
the intestines throughout the body. A certain percentage of the
drug is always bound to the protein. Only the unbound, or free,
portion of the drug can work. Thus, binding is important in
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determining how much drug will be available to produce the desired
effect. With age, there is a decline in the amount of albumin,
one of the blood proteins. Some drugs are highly bound to albumin,
including the epilepsy drug Dilantin, Valium, and blood-thinning
drugs (Dicumarol). A reduction in albumin will result in an
increased amount of active drug, so what would normally be a
therapeutic dose of the drug may prove to be a toxic one. Still
other problems may develop because drugs compete for these binding
sites. When one drug is blocked at the binding site by a second
drug, the amount of the first drug that is freely circulating
increases, as does the potential for toxicity. For example,
phenylbutazone, salicylates, and sufonamides can displace
tolbutamide (a drug for treating diabetes), leading to
hypoglycemia.
Metabolism also changes with age. Drug metabolism rates in the
elderly are one-half to two-thirds the rates of middle-aged and
younger patients. Metabolism takes place primarily in the liver,
where drugs are changed into water-soluble form so that they can
be excreted. One drug may stimulate the metabolism of another,
thus decreasing its effectiveness. Phenobarbital has this effect
on anticlotting drugs. On the other hand, the antibiotic chlor-
amphenicol slows the metabolism of these drugs, thereby increasing
the magnitude and duration of their effects. The capability of
the liver to perform this vital function depends on the blood flow
to that organ. In the elderly, this blood flow is decreased.
Drugs ingested orally, including beta blockers, narcotics,
nitrates, hydralazine, and tricyclic antidepressants pass through
the liver before they reach the general circulation. Because of
the reduced blood flow, smaller amounts of these drugs are metab-
olized and excreted. Consequently, the amount that enters the
elderly person's system is higher than it should be.
Finally, the body's processes for eliminating drugs can be im-
paired in the elderly because of changes that occur in the aging
kidney, changes that are more dramatic than those in any other
organ. The kidneys become smaller, as blood flow and filtering
capacity decrease. Such kidney impairment retards the elimination
of water-soluble drugs such as digoxin, certain antibiotics,
chlorpropamide, and hypotensive agents, leaving the elderly
patient more prone to adverse drug reactions.
INCREASED SENSITIVITY TO DRUGS IN THE ELDERLY
As if this weren't enough, the elderly appear to be more sensitive
to certain drugs. For instance, they seem to be more affected by
anticholinergic drugs. These drugs can cause confusion, disorien-
tation, hallucinations, and delirium, as well as blurred vision,
dry mouth, palpitations, and constipation in the elderly. Among
anticholinergics are medications for spastic colon, drugs used for
treatment of Parkinson's disease, some antihistamines, tricyclic
antidepressants, and drugs to control irregular heartbeats. Older
patients may experience fainting and dizzy spells from drugs such
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as antidepressants, which don't usually produce such effects in
younger patients. Older women also seem to be more sensitive to
diazepam, thus requiring smaller doses than younger patients.
Nonprescription, or over-the-counter (OTC), drugs have a prominent
place in the medicine cabinets of most elderly people. Analgesics
(painkillers), antacids, cough and cold preparations, and laxa-
tives are among the OTC drug products most frequently used by
older people. While many people don't think of these as drugs,
OTC drug products can be the cause of adverse side effects in
older patients. Aspirin, for instance, can increase the effect of
blood thinners, and decrease sodium and chloride excretion--a mat-
ter of concern to those with congestive heart failure. Chronic
use of aspirin may lead to iron deficiency anemia. Antacids can
interfere with the absorption of some drugs, such as the antibi-
otic tetracycline, while chronic use of laxatives can lead to
electrolyte and water balance disturbances.
While many elderly people may have some vitamin deficiencies,
treatment with megadoses of vitamins is generally not recommended.
One reason for avoiding them is the side effects of such doses.
Too much vitamin C may raise uric acid levels and trigger gout in
those disposed to this painful disease. Vitamin C can also cause
false readings on urine tests essential to control diabetes. Too
much vitamin A can be the cause of fatigue, malaise and lethargy.
It would seem that the best way to avoid adverse reactions in
older patients is simply to reduce the amount and number of drugs
they take. However, prescribing for the elderly, like life
itself, is not simple. The changes that come with age often are
gradual, and patients, being individuals, do not necessarily age
at the same rate. Drug manufacturers, for the most part, do not
test their products in elderly patients, and there are no easy,
clear guidelines to determine how much or little of a drug a par-
ticular patient will need. To solve some of these problems, the
Food and Drug Administration, encouraged by the American Associa-
tion of Retired Persons and the National Institute on Aging, is
looking into the development of guidelines for geriatric testing
of drugs.
One should not forget that, since older women suffer from multiple
chronic illnesses and are users of multiple drugs, nutrition
becomes a major health concern for this population, as these ill-
nesses and concomitant drug use often interfere with the ability
to eat and absorb foods needed for good nutrition.
CONCLUSIONS AND RECOMMENDATIONS
A comprehensive strategy will be necessary to respond to the grow-
ing crisis of resource shortages in the face of expanding numbers
of older women, and a clear policy is needed regarding the health
issues of older women. All relevant agencies at the State and
Federal level should include this topic as a research priority.
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The strategy needs to conceptualize aging women to include middle
and later life, and needs to address the double jeopardy of agism
and sexism. To be most effective, a strategy will require an
integrated approach to the multiple factors influencing the health
of elderly women and will respond to high-risk subgroups of older
women. Solutions that strengthen informal caring are both cost-
effective and practical; these can be integrated with formal re-
sources.
The planning and implementation of a strategy to address the
health issues of aging women will require research, education, re-
source coordination, legislation, advocacy, and insurance. The
initiative now begun must continue to define areas of need and to
distinguish the needs of the very elderly woman, whose risks are
immediate and linked to long-term care, from those of the woman
who is chronologically old but functioning at a high level, at
least until she experiences health and economic deficits. It
should also reflect the needs of the middle-aged woman dealing
with life transitions and managing dependent people, and those of
the younger woman with an old age to plan for.
A response to the health needs of older women requires continuity
that incorporates a futuristic orientation with the imperatives of
the present. To plan an effective current and future strategy,
broad priorities must be matched with a comprehensive research
agenda and educational efforts. A comprehensive research agenda
would address the normal aging process as well as the pathological
models. Furthermore, biomedical, applied health care, social
science, and clinical intervention research are all part of this
research agenda. To date, all types of research have neglected to
design studies that compare older men with women, younger with
older women, and subgroups of older women with each other. In
studies where such data have been collected, information related
to older women's concerns is either only partially analyzed or not
readily accessible in published form.
The field is wide open to the creative investigator. New analyti-
cal procedures may need to be discovered and applied to produce
reliable data about the interaction of age and gender variables.
Health survey research, program design, and outcome studies need
to be increased in number and scope.
Significant educational advances have been made in medical,
nursing, social work, and other key professions as they shift
toward more gerontological and geriatric content, but much of the
curriculum is devoid of gender-related information. Clinical
training often fails to reduce myths and stereotypes held by
practitioners about older women. The focus of education can
transcend the narrow pathological/disease perspective and move
toward an understanding of function and dysfunction within an
environmental perspective. With this understanding, economic
resources in support of gerontological and geriatric education can
be distributed effectively among the relevant disciplines, to
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improve training and continuing education, so that the older woman
is better served.
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Gender as a Factor in
Treating the Elderly
Patricia P. Barry
THE ELDERLY
Chronologic age alone does not account for the increased incidence
of drug toxicity with advancing years. Elderly persons have more
disease, often severe and of long duration, requiring more medica-
tions. In addition, factors such as nutrition, mental status,
functional capacity, and use of alcohol and cigarettes are impor-
tant. In these respects, as in many others, the elderly comprise
a heterogeneous group that must be carefully evaluated, on an
individual basis, in the treatment of illness.
Several problems are common in the clinical practice of geriat-
rics. The elderly often are afflicted with multiple diseases.
Heart disease. cancer, chronic lung disease, and Alzheimer's
disease, which are major causes of death in the elderly, may also
lead to chronic ill health. Additionally, functional impairment
due to arthritis, impaired vision and hearing, and depression may
limit the elderly person's ability to attend to personal needs, or
to maintain mobility and adequate nutrition. The clinician must
also consider the management of such common diseases as diabetes
and hypertension in the treatment plan.
PHYSIOLOGIC CHANGES
Biological changes of aging have been recognized as important fac-
tors to be considered in planning drug therapy. Gastrointestinal
changes, such as increased gastric pH, increased gastric emptying
time (Stevenson et al. 1979). and decreased active transport
(Bender 1968). have been noted in clinical studies. In the renal
system, function declines in many elderly patients, even in the
absence of renal disease. Such parameters as glomerular filtra-
tion, as well as tubular secretion and absorption, may be reduced
as much as 35 percent (Rowe et al. 1976). Due to decreased endog-
enous production of creatinine (Vestal 1978). serum creatinine,
which is a measure used to indicate kidney function, may not re-
flect the decrease in creatinine clearance, which may be as much
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as 10 ml/min/decade (Kampmann et al. 1974). Cockcroft and Gault
(1976) developed a useful formula for calculating estimated
creatinine clearance in the elderly:
Creatinine Clearance = (140-age) body weight
72 x serum creatinine
The hepatic changes in the elderly are not usually reflected by
abnormalities in the standard liver function tests. Not only can
the production of albumin decrease, but reduced hepatic blood flow
may be a major determinant of the prolonged metabolism of many
drugs (Geokas and Haverbach 1969). Microsomal enzyme activity,
especially hydroxylation (a Phase I reaction) is often reduced in
the elderly (Greenblatt et al. 1982). Body composition altera-
tions in the elderly include a reduction in lean body mass (Forbes
and Reina 1970) and total body water (Novak 1972), and an increase
in adipose tissue mass, which may be even more significant in
elderly women than in elderly men (Greenblatt et al. 1982).
ALTERED PHARMACOKINETICS
The changes noted may affect the pharmacokinetics of many medi-
cations in the elderly patient. Absorption, reviewed by Stevenson
et al. (1979), has not been shown to significantly decrease in
most elderly persons. The drugs so far studied, however, are
among those known to have good absorption properties in the gen-
eral population, and it is possible that drugs known to be poorly
absorbed will show decreased absorption by the elderly.
Drug distribution is influenced by the volume of distribution and
the extent of protein binding. Drugs that are lipid soluble may
have an increased volume of distribution in the elderly, due to
the increased proportion of adipose tissue, especially in women.
The volume of distribution for water-soluble drugs is contracted
in many elderly, resulting in higher plasma levels. Finally,
drugs that are extensively bound to albumin may have increased
levels of unbound drug in the elderly, if the serum albumin is
decreased.
Clearance is primarily a function of the liver and kidney, and is
dependent upon blood flow to these organs. In elderly patients
with diminished perfusion, therefore, clearance may be reduced due
to decreased renal elimination and hepatic metabolism.
Both volume of distribution and clearance of a drug will affect
the serum half life by the following relationship:
t 1/2 = 0.693 x Volume of distribution
clearance
Persons with increased volume of distribution or decreased
clearance, or both, will have increased serum half life (t l/2)
and greater susceptibility to drug toxicity (Greenblatt et al.
1982).
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DRUG PROBLEMS
In several studies of compliance reviewed by Vestal (1978), the
elderly were found to have serious difficulties. Error frequen-
cies ranged from 25 to 50 percent, and were often due to lack of
understanding of drug regimens. Vestal also noted that the
incidence of drug reactions is higher in the elderly, ranging from
15 to 24 percent in hospital settings. Drugs that may cause
problems include digoxin, diuretics, antihypertensives, anticoagu-
lants, bronchodilators, analgesics, sedative-hypnotics, antide-
pressants, and antipsychotics. Drug toxicity may be manifested by
confusion, sedation, hypotension, fluid and/or electrolyte distur-
bances, cardiac arrhythmias, anorexia, urinary retention, and many
other common complaints.
GENDER DIFFERENCES
Greenblatt et al. (1982) noted that the body proportion of adipose
tissue increases with age, from 18 to 36 percent in men and from
33 to 48 percent in women. Women have a larger volume of distri-
bution of lipid-soluble drugs, and a smaller volume of distribu-
tion for water soluble drugs. Decreased protein binding in women
has been noted in some studies, but data are conflicting (Wilson
1984). However, diminished activity of hepatic oxidative enzymes,
resulting in decreased drug clearance has been found to be more
significant in elderly men than in elderly women (Greenblatt et
al. 1982).
DRUG STUDIES
Sex-related differences have been studied by Greenblatt and co-
workers, and reported for diazepam, desmethyldiazepam (an active
metabolite), oxazepam, and temazepam; half-life of these drugs is
consistently longer in women (Wilson 1984). Gender differences in
oxidation are important in the metabolism of these drugs; for
oxazepam and temazepam, the clearance rate is higher in men
(Greenblatt et al. 1980a, Divoll et al. 1981); for diazepam and
desmethyldiazepam it is lower in men (Greenblatt et al. 1980b;
Ochs et al. 1981; Allen et al. 1980). The increased half-life of
the latter drugs in women is apparently related to their greater
volume of distribution for these lipid-soluble drugs.
Other drugs in which gender differences have been observed include
heparin, which has greater adverse effects in women (Greenblatt et
al. 1982), and imipramine, which is less protein-bound in women
(Kristensen 1983). Goble (1975) has extensively reviewed a number
of drugs for sex-related differences in response or side effects.
TREATMENT CONSIDERATIONS
Elderly women differ in other important respects from elderly
men. They are more likely to be widowed, live alone, or reside in
an institution; many have reduced income. (Elderly men more often
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reside with their spouses, and often have the assistance of veter-
ans' benefits.) Medical problems such as osteoporosis and urinary
incontinence are more common in women, in addition to the obvious
importance of medical problems specific to women, such as cancer
of the breast, ovary, and uterus.
In the field of geriatric medicine, considerable attention has
been directed to the problems associated with prescription drug
use and misuse. Little attention has been directed to the
specific considerations of elderly women, despite the fact that
our population becomes increasingly female with age. Most drug
studies comparing women with men have considered only younger
women and have emphasized such factors as pregnancy, menstruation,
and the use of oral contraceptives, despite the fact that women
today live one-third of their lives after menopause. Future
research must therefore address the physiologic, pharmacologic and
socioeconomic factors that contribute to gender differences in our
elderly population.
REFERENCES
Allen, M.D.; Greenblatt, D.J.; Harmatz, J.S.; and Shader, R.I.
Desmethyl diazepam kinetics in the elderly after oral praze-
pam. Clin Pharmacol Ther 28:196-202. 1980.
Bender, A.D. Effect of age on intestinal absorption: Implica-
tions of drug absorption in the elderly. J Am Geriatr Soc
16:1331-1339, 1968
Cockcroft, D.W., and Gault, M.H. Prediction of creatinine
clearnace from serum creatinine. Nephron 16:31-41, 1976.
Divoll, M.; Greenblatt. D.J.; Harmatz, J.S.; and Shader, R.I.
Effect of age and gender on disposition of temazepam. J Pharm
Sci 70:1104-1107, 1981.
Forbes, G.B., and Reina, J.C. Adult lean body mass declines with
age: Some longitudinal observations. Metabolism 19:653-663,
1970.
Geokos, M.D., and Haverbach. B.J. The aging gastrointestinal
tract. Am J Surg 117:881-892, 1969.
Goble, F.C. Sex as a factor in metabolism, toxicity and efficacy
of pharmacodynamic and chemotherapeutic agents. In: Garattini
et al., eds. Advances in Pharmacology and Chemotherapy Vol.
13. New York: Academic Press, 1975. pp. 174-252. 
Greenblatt, D.J.; Allen, M.D.; Hirmatz; J.S.; and Shader, R.I.
Diazepam disposition determinants. Clin Pharmacol Ther 27:301-
302, 1980a.
Greenblatt, D.J.; Divoll, M.; Harmatz, J.S.; and Shader, R.I.
Oxazepam kinetics: Effects of age and sex. J Pharmacol Exp
Ther 215:86-91, 1980b.
Greenblatt, D.J.; Sellers, E.M.; and Shader, R.I. Drug
disposition in old age. N Engl J Med 306:1081-1088, 1982.
Kampmann, J.; Siersbaek-Nielsen, K.; Kristensen, M.; and Molholm
Hansen, J. Rapid evaluation of creatinine clearance. Acta Med
Scand 196:517-520, 1974.
68
Kristensen, C.B. Imipramine serum protein binding in healthy
subjects. Clin Pharmacol Ther 34:689-694, 1983.
Novak, L.P. Aging, total body potassium, fat free mass and cell
mass in males and females between the ages of 18 and 85. J
Geronotol 27:438-443, 1972.
Ochs, H.R.; Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.;
Feyerabend, H.; and Dingler, H.J. Diazepam kinetics in relation
to age and sex. Pharmacology 23:24-30, 1981.
Rowe, J.W.; Andres, R.; Tobin, J.D.; Norris, A.H.; and Shock,
N.W. The effect of age on creatinine clearance a man: A
cross-sectional and longitudinal study. J Geronotol 31:155-163,
1976.
Stevenson, I.H.; Salem, S.A.M.; and Shepard, I.M.M. Studies on
drug metabolism and absorption in the elderly. In: Crooks, J.
and Stevenson, I.H., eds. Drugs and the Elderly. Baltimore:
University Park Press, 1979. pp.51-63.
Vestal, R.E. Drug use in the elderly: A review of problems and
special considerations. Drugs 16:358-382, 1978.
Wilson, K. Sex-related differences in drug disposition in man.
Clin Pharmacokinet 9:189-202, 1984.
AUTHOR
Patricia P. Barry, M.D.
Geriatric Section
Department of Medicine and
Home Medical Service
Boston University Medical Center
Boston, Massachusetts
69
Gender and the Teenage Smoker
Ellen R. Gritz
INTRODUCTION
Cigarette smoking is no longer a behavior that is considered nor-
mative for men but socially disapproved for women, thus undertaken
in secret, or openly as a symbol of risque or avante guarde femi-
nism. As a result of sweeping changes in social forces during
this century, cigarette smoking became an acceptable behavior for
both males and females. We are thus witnessing the "disinhibi-
tion" of a problem, the emergence of a problem-in-waiting.
Women's smoking prevalence increased from 18.1 percent in 1935 to
33.3 percent in 1965 and has since decreased to 29.5 percent in
1983; in comparison, men's smoking prevalence decreased rather
steadily from 52.5 percent in 1935 to 34.8 percent in 1983 (USDHHS
1980; NCHS, in press). The mean age of initiation of smoking
among successive birth cohorts of women smokers from 1900 to 1960
has dropped to approximately the same mean age as men (USDHHS
1980). Interestingly, these great changes in women's smoking be-
havior have been paralleled by an unrivalled direct-appeal cam-
paign by cigarette advertisers, which began in the mid- to late
1920’s (Howe 1984).
The trend data describing women's smoking prevalence are not new,
so why should it suddenly be considered the disinhibition of a
problem? What is news in 1985 is the actualization of a National
tragedy that was totally preventable--the emergence of lung cancer
as the number one cause of cancer mortality among women, surpas-
sing breast cancer (American Cancer Society 1985). In 1985, it is
predicted that 38,600 women will die of lung cancer versus 38,400
of breast cancer. Lung cancer has become a major problem for wom-
en as a result of the dramatic increase in women's smoking just
described. A disease that virtually did not exist in this country
at the turn of the century is now killing more men and women annu-
ally than any other form of cancer (American Cancer Society 1985).
The charge of this paper, however, is to concentrate on adolescent
smoking and to speculate on some of the psychosocial factors which
may promote smoking in teenage girls.
70
TRENDS IN CIGARETTE SMOKING AMONG ADOLESCENTS
Lagging behind, but paralleling changes in the smoking patterns of
adult women, have been widespread changes in teenage smoking.
However, "equality" in smoking behavior had been reached in ado-
lescents prior to adults. National survey data show that gender
differences in teenage cigarette smoking have virtually dis-
appeared, and that female smoking now exceeds that of males for
most analyses (Johnston et al. 1985; NIE 1979; Clayton, this
volume). A series of cigarette smoking surveys among 12- to 18-
year-olds was conducted by the National Clearinghouse for Smoking
and Health and the National Institute of Education between 1968
and 1979 (NIE 1979). While a greater percentage of boys (14.7
percent) than girls (8.4 percent) smoked at the time of the 1968
survey, smoking prevalence increased steadily among girls until
the 1979 survey, when the first evidence of a decline appeared.
Smoking among boys began to decrease beginning with the 1972
survey. By 1979, the prevalence of smoking was higher among girls
(12.7 percent ) than among boys (10.7 percent). Although a
National survey of smoking behavior in the 12- to 18-year-old age
group has not been conducted since 1979, one is planned by the
Office on Smoking and Health (Shopland, personal communication).
A second source of National data describing teenage smoking pat-
terns comes from the Monitoring the Future project, a survey of
drug use among high school seniors, conducted annually since 1975
by investigators at the University of Michigan Institute for
Social Research and sponsored by the National Institute on Drug
Abuse (Johnston et al. 1985). Between 1977 and 1980, the preva-
lence of cigarette smoking fell by nearly one-third and then lev-
eled off for several years. The most recent survey showed the
prevalence of daily use among high school seniors to be 18.7 per-
cent in 1984--a reduction of 2.5 percent from the 21.2 percent
prevalence in 1983 and a resumption of the downward trend
(Johnston et al. 1985).
Gender-specific data revealed a higher prevalence of smoking among
girls at levels of occasional smoking--one or more cigarettes per
month (F=31.9 percent, M=25.9 percent) and one or more cigarettes
per day (F=20.5 percent, M=16.0 percent). However, this gender
difference decreased as consumption levels increased to one-half
pack or more per day (F=12.8 percent, M=11.0 percent) and one pack
or more per day (F=6.2 percent, M=6.6 percent), until approximate
parity was reached at the latter consumption level, characteristic
of adult smoking behavior. Figure 1 shows temporal trends by sex
in daily cigarette smoking for any daily use and for one-half pack
or more per day, and simultaneously displays temporal trends in
daily use of marijuana and alcohol (Johnston et al. 1985). The
trends for the three drugs are obviously quite different, with
only cigarettes showing the reversal of the higher prevalence from
males to females.
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FIGURE 1. Trends in 30-day prevalence of daily use of marijuana,
alcohol, and cigarettes, by sex
NOTE: Daily use for alcohol and marijuana is defined as use on 20 or more occa-
sions In the past 3O days. Daily use of cigarettes is defined as smoking
one or more cigarettes per day in the past 30 days.
SOURCE: Johnston e+ al. Use of licit and illicit drugs by America’s high school
students, 1975-1904. DHHS Pub. No. (ADM) 05-1394, 1985.
THE DEVELOPMENT OF SMOKING BEHAVIOR
Adolescent females have been characterized by cognitive and emo-
tional immaturity, hypersensitivity to peer rejection, vulnerabil-
ity to impulsive behavior, and difficulty in acquiring a positive
body image (Freedman 1984). The combination of these four dimen-
sions makes the teenage female exquisitely vulnerable to the se-
ductive allure of smoking. Developmental models of the initiation
of smoking behavior, such as that of Flay et al. (1983), set out
factors predisposing to cigarette smoking; these may be biologi-
cal, environmental, and/or psychological.
In the preparation or anticipation stage, family influences pre-
dominate. Thus, watching parents or older siblings smoke facili-
tates the development of a positive attitude toward smoking in the
cognitively and emotionally immature girl and teaches her how,
when, and where smoking is appropriate. The presence of smoking
in the home will accustom her to the smell and sight of cigarettes
and will also expose her passively to some of the health damaging
effects of cigarette smoke, as well as teaching her to imitate the
physical actions of smoking, if she is so inclined. As evidence
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for this family influence, data show a fivefold increase in like-
lihood (20.3 percent versus 4.1 percent) that an adolescent girl
will smoke if she is in a household in which one or both parents
or an older sibling smoke compared to a household in which none of
these persons smoke (NIE 1979).
During the period of initiation, trying the first cigarette, peers
become most important. This is a period of social transition and
of movement to a school more distant from home, a time where
hypersensitivity to peer rejection may lead a young girl to accept
the offer of a cigarette all too easily from a valued set of
friends. Fifty percent of all first cigarettes are smoked with a
friend (Bewley et al. 1974; Friedman et al. 1985; Palmer 1970),
and almost 75 percent of all first cigarettes are smoked with
another teenager (Biglan et al. 1983). Friedman et al. (1985) re-
ported that 60 percent of all first-cigarette experiences or pres-
sures to smoke occurred in the teenager's own home or in that of a
friend, suggesting acceptance (or ease of sneak experimentation)
in the two main social settings for this age group. Indeed, par-
ents were even present in 7 percent of the first-cigarette inci-
dents reported in that study. Teenage smokers stick together, as
do nonsmokers, and initial experiences occur most frequently with
persons of the same sex (Friedman et al. 1985; NIE 1979). Life-
style choices are beginning to be made at this time, and may
include a variety of behaviors and value orientations into which
the image of a smoker fits (Wang-McCarthy and Gritz 1982).
The period of learning and becoming, experimental smoking, is
operationally defined as smoking less than one cigarette per week.
In this period of social reinforcement, the formation of a self-
image is occurring. Thus, impulsive behaviors like smoking and
experimentation with alcohol and sex may occur when socially
prompted. The image of a smoker, described by both personality
and physical attributes, can become highly valued and identified
with; teenage girls may see smoking as a way to acquire such an
image. McCarthy and Gritz (1984) demonstrated that the closer the
ideal self-image of a smoker was to her/his description of a model
in a cigarette advertisement, the more likely that adolescent in-
tended to be a smoker (Barton et al. 1982; Chassin et al. 1981).
In this stage of the model as well as in the following stage, the
physical image of the female smoker portrayed in advertisements
may wield substantial power. Also in this and the following
stage, the smoker learns to regulate the nicotine dose of a
cigarette, to become accustomed to its mood-altering and other
pharmacologic effects, and to begin a pattern of conditioned re-
inforcement from smoking.
The final stage in the developmental model of smoking, habitua-
tion, is achieved when the adolescent is smoking at least one
cigarette weekly. National surveys use this level to define
regular smoking in the age group 12 to 18 years (NIE 1979).
Dependence can begin to develop about this time. Skilled, by this
stage, in techniques of inhalation and nicotine/dose regulation,
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the teenage girl may especially learn to use cigarettes as a legal
and sanctioned means of weight control, also highly valued during
this period.
VULNERABILITIES FOR ADOLESCENT FEMALES: WEIGHT MD ADVERTISING
Using the developmental model for smoking for a teenage girl, it
becomes easier to see how standards of slenderness and weight loss
may be related to smoking and how cigarette advertising may capi-
talize on these and other descriptions of female beauty.
Feminine beauty has been equated with ultraslimness for a genera-
tion (Freedman 1984). Obsession with reducing body weight and the
existence of serious eating disorders is increasingly prevalent
among teenage girls and women today (Wooley and Wooley 1984; Yager
1985). Almost 20 years ago, Dwyer et al. (1967) reported that by
the end of high school 60 percent of girls had already been on a
serious diet and half that number were dieting at any one time
(compared to 24 percent and 6 percent, respectively, for boys).
Current data from the NIDA High School Senior Survey (Johnston et
al. 1985) show an astounding use of nonprescription diet pills
among female high school seniors: ever used, but not in past
year--43 percent (versus 15 percent for boys); used in the past
year, not in past month--27 percent (versus 9 percent for boys);
used in past month, less than daily--l4 percent (versus 5 percent
for boys); and used daily in the past month--l.9 percent (versus
0.3 percent for boys). Interestingly, in the Glamour Magazine
survey of 33,000 women, 50 percent of respondents reported using
diet pills sometimes or often (Wooley and Wooley 1984). Analysis
of the NIDA teenage data for concurrent use of reducing pills and
cigarettes has not been reported, but an association might be pre-
dicted. Teenagers who smoke are more likely to have tried other
substances such as alcohol and marijuana, and to engage in problem
behaviors. The gateway theory of substance use predicts the order
in which licit and illicit drugs are introduced, and analyses have
been performed on continuation and discontinuation patterns
(Jessor and Jessor 1977; Kandel 1978; Kandel and Logan 1984;
O'Malley et al. 1984).
A recently published study (Charlton 1984) of smoking behaviors
and beliefs conducted on 16,000 British children and adolescents
revealed several fascinating relationships between beliefs about
cigarette smoking and weight control:
Across all respondents, the proportion agreeing that "smoking
keeps your weight down" rose steadily from 16.6 percent in
never smokers to 42.2 percent in the heaviest smokers (more
than six cigarettes per week).
This increase was more pronounced in girls than boys, and,
among regular smokers (at least one cigarette per week) at all
ages, girls were more likely than boys to agree that smoking
controls weight.
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Concurrent with the advent of puberty, the belief among regular
smokers that smoking controls weight takes a sharp increase,
from 5.0 percent among 9- to 11-year-old girls to 35.7 percent
in 12-year-old females. This belief rises steadily to a peak
of 52.9 percent among 16-year-olds, the age at which a sharp
drop in the percentage of males agreeing (29.0 percent) occurs.
The authors note that among the various belief questions on the
survey, only the question of weight control mirrors the post-
pubertal rise in girls' smoking so closely. Comparable data
for the United States are greatly needed, and could possibly be
collected, along with the type of information in the NIDA High
School Senior Surveys.
Cigarette smoking provides a lifestyle crutch with a physiological
basis to facilitate weight control. Stimulation of the gastro-
intestinal tract by nicotine results in increased tone and motor
activity of the bowel (Gilman et al. 1980). Anecdotally, smoking
a cigarette is said to suppress appetite; thus, smoking serves as
a means of delaying eating or reducing consumption. Cigarettes
are also often used to mark the end of a meal and frequently
accompany coffee and alcohol consumption (McKennell and Thomas
1967 ). Thus, the ritual aspects of smoking and eating/drinking
may come to represent social competence to an adolescent girl,
along with an image of physical attractiveness.
This brings us to the putative role of cigarette advertising in
female smoking, a highly debated influence with regard to the ini-
tiation of smoking. Pictorial advertising portrays smoking as
fun, sophisticated, sexually adventurous, and involving risk tak-
ing (FTC 1981; FTC 1985; Yankelovich et al. 1977). At the very
least, we can say that cigarette advertising provides an indirect
Influence on smoking onset by supporting the image of smoking as a
symbol of maturity, autonomy, and attractiveness.
These admired traits, and those mentioned above, form part of the
myth surrounding the social benefits of smoking (Chapman and
Fitzgerald 1982). Girls learn far earlier than puberty that
beauty is a primary dimension of femininity; by adolescence, the
cultivation of attractiveness has become a major task (Freedman
1984). Girls also grow up surrounded by omnipresent models of
beautiful women on billboards, television, in movies and maga-
zines, which are capable of influencing their evaluation of the
importance of beauty for attaining popularity. Combined with the
fact that early adolescence marks the highest degree of anxiety
and greatest dissatisfaction with body image (Freedman 1984), the
allure of cigarette ads targeted at women can be immense. Every
psychosocial attribute and culturally relevant message valued in
this age group can be found in cigarette ads which feature, in
addition to those attributes mentioned earlier, athletics, dress,
favorite activities, feminism, and very frequently, extreme
slenderness.
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The most recent Federal Trade Commission Report to Congress Pursu-
ant to the Federal Cigarette Labeling and Advertising Act (Federal
Trade Commission 1985) contains an analysis of cigarette advertis-
ing practices and expenditures for the years 1982-1983. In those
years, ads directed primarily toward females featured glamorous
and elegant women, and a "luxury brand" was introduced. The FTC
Report summarizes the advertising approach as follows: "The ciga-
rette marketers placed increasing emphasis on linking a particular
brand with health, wealth, luxury, and achievement."
To note that cigarette manufacturers spent a total of $2.65 bil-
lion in 1983, compared to $1.2 billion in 1980, may serve to
illustrate the degree of environmental flooding that is possible
with a media campaign. The three forms of media on which the
greatest amounts of money were spent for advertising in 1983 were
magazines, newspapers, and outdoor displays, in decreasing order.
Public entertainment or special events, including sports, musical,
and other cultural events, received increased sponsorship. This
included such sporting events as Team America Pro Soccer, the
Western Rodeo series, Ski Days, the Virginia Slims Tennis Tourna-
ments, and the Raleigh Children's Cancer Classic Celebrity golf
Tournament. Cigarette advertising and giveaways, such as T-shirts
with a brand logo, were frequently prominent at such events.
Examples of cultural events sponsored in whole or part by the
cigarette industry were the Kool Jazz Festival and the New York
City Opera Company's National tour. Obviously, many of these
events are attended by adolescents, who may even come to associate
such attractions with particular brand images.
Recently, Warner (1985) has written convincingly regarding media
self-censorship on the known relation between smoking and health.
He cites several sources of self-censorship, the primary one being
the fear of publishers that advertising will be withdrawn and thus
substantial revenues lost if the health effects of smoking are
openly addressed. Additionally, advertisements for antismoking
products and services may be rejected by publishers for fear of
offending the tobacco advertisers. Warner states, "Evidence...
strongly suggests that the public is fed a media diet deficient in
news, comment, and commercial promotion relating to the adverse
consequences of smoking."
With specific regard to women's magazines, Whelan et al. (1981)
reported that only eight feature articles on smoking or quitting
were published in the 12 years between 1967 and 1979 in 10 leading
magazines that carried cigarette advertising. Twice as many (16)
such articles appeared during the same time period in two women's
magazines that do not carry cigarette advertising. Compared to
the dangers of smoking, far greater attention was given to other
women's health issues, such as contraception, stress, mental
health, and nutrition, in the magazines that accept cigarette ad-
vertising than in those that do not. Thus, there is a very clear
source of bias in the amount of information about health issues, in
general, and about smoking in particular, that an adolescent
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female will encounter if she reads women's or other magazines
which accept cigarette advertising. The female adolescent must
somehow overcome this source of misinformation if she is to avoid
habitual use of tobacco and increased risk of cancer.
DIRECTIONS FOR FUTURE HEALTH EDUCATION
To make nonsmoking appealing and counter the extremely sophisti-
cated images presented by cigarette advertisers constitutes a
major task for researchers and educators from the fields of school
and public health, the medical professions, and health psychology
(Gritz 1984; Howe 1984). Prevention programs often do not address
the lifestyle choices and values of those adolescent girls most
likely to take up smoking--those who are disinterested in school,
not college-bound, who are precocious in social and sexual behav-
iors, and who may especially value the images peddled by adver-
tisements (NIE 1979; Yankelovich et al. 1977). In addition, the
health risks to fetus and mother associated with smoking in preg-
nancy, especially low birth weight, are important to remember
since low birth weight is a major problem for teenage mothers
(USDHHS 1980; USDHHS 1981). Parental smoking also elevates risk
of respiratory disease in infants (USDHHS 1980). Thus, the teen-
age female smoker may be at risk for immediate as well as future
health consequences. We need to learn to "market" nonsmoking to
this population of young women in ways they will find attractive.
using role models they adulate. In light of the worrisome preva-
lence trends of the mid-1980's. this may be our foremost under-
taking in smoking prevention for women.
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Gender Differences in
Drug Use: An Epidemiological
Perspective
Richard R. Clayton, Harwin L. Voss, Cynthia Robbins,
and William F. Skinner
The purpose of this paper is to
differences in drug use. This
of what is known about drug use
provide a broad overview of gender
is a formidable task because much
is based on studies of males.
Further, drug use is a heterogeneous phenomenon, involving a vari-
ety of drugs having effects that vary with circumstance. Specifi-
cally, this paper will examine:
the prevalence of use of several drugs by men and women in
different age groups (youth, 12 to 17 years old; young adults,
18 to 25 years old; mid-adults, 26 to 34 years old; and older
adults, 35 years old or older);
the use of psychotherapeutics medically and nonmedically, by
sex and age group; and
differences in age at onset of use of various drugs, by sex and
age.
The findings are based on data obtained in the 1982 National
Survey on Drug Abuse through personal interviews with 5,624
individuals 12 years old or older. Before examining these
specific issues, however, we will review the broader societal
context within which drug use and abuse by women has become a
topic of major concern for public health professionals.
THE SOCIETAL CONTEXT OF PUBLIC HEALTH ISSUES
Some social issues are, by nature, temporary, being prominent for
a period of time until the public turns its attention to other
concerns. During the early 196Os, under the banner of civil
rights, the twin issues of poverty and discrimination were prom-
inent. During the late 1960s and early 1970s, the war in Vietnam
was the major issue. As historians describe the past they often
label eras by the issues that dominated the public's attention.
Thus, references to the "civil rights" era and the "Vietnam' era
invoke images that link us as individuals to forces at the
societal level that influenced our lives.
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Other social issues are, by nature, lingering or perhaps perma-
nent, remaining prominent over longer periods of time and sus-
taining the public's attention. One such issue is drug abuse,
which has been of growing public concern for almost two decades
since the epidemic of marijuana use emerged in the mid-1960s
(O'Donnell et al. 1976). One reason drug abuse has continued
salience may be that the "drug scene" appears as constantly In
flux. New drugs emerge, such as PCP and MDMA, or old drugs take
fashion, such as cocaine, and a new epidemic threatens the public
health.
Issues of public health and policy often link together, as new
issues are seen in the context of matters already of public-policy
concern. This has been the case for women's issues, ignored until
quite recently. The existence of a conference focused on gender
differences in drug use and abuse is one example of this linking
of issues.
This linkage is timely. In the past, drug abuse research has
focused too often exclusively on men, on only one class of drugs,
such as opiates. or on one type of user, such as addicts. One
cannot understand drug use and abuse in the United States by
studying only male opiate addicts, just as one cannot understand
alcohol abuse and problem drinking by studying only skid row alco-
holics. In view of this, the mistakes of the past should not be
continued by focusing exclusively on drug use and abuse among
women, but rather both genders should be studied at the same time
to reveal differences and similarities. More can be learned by
studying gender as a variable, by comparing the patterns of drug
use of men and women, than by studying either sex alone. While a
few research questions are gender-unique in the drug field, for
Instance, the influence of drugs on the neuronal and hormonal
processes In the menstrual cycle (Mello, this volume), the major-
ity of important questions about women's drug use and abuse are
best addressed from a comparative perspective, using gender as an
experimental variable.
BASIC ASSUMPTIONS
In addition to the assumption that a comparative approach offers
a promising way to examine drug use and abuse by women, several
additional assumptions underlie this paper.
First, production of knowledge takes time. The two national
institutes dedicated to the study of substance abuse, alcohol and
drug abuse, have been in existence for only 10 years. Instead of
chastising ourselves for how little is known about gender differ-
ences in drug use, a more constructive approach would be to note
how much has been learned in such a short time.
Second, while the differences between men and women have been of
interest to poets, novelists, and philosophers for many years,
only recently have social scientists devoted serious attention to
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gender differences. The reason sex differences have been ignored
is simple. For most of human history the lives of men and women
were essentially on separate paths. There was a man's world and a
woman's world. Obviously, this situation has changed markedly in
the past 20 to 30 years. As options have expanded for both sexes,
men and women are doing things now that never would have occurred
in the past. There is considerable diversity in the behavioral
options available for both sexes and considerable overlap in those
options.
Finally, disciplinary disputes within the field of drug abuse
appear to be dissipating, and the various disciplines now acknowl-
edge the relevance of fields besides their own. Sociologists, for
example, recognize that once the variables they consider to be
relevant have been measured, a substantial amount of variance in
drug use is left unexplained. The unexplained variance may be
accounted for by independent variables favored by other disci-
plines. This recognition accounts, in part, for the ascendance of
gender differences in drug use as important for public policy. By
focusing exclusively on men or women, information is lost about
gender as an independent variable affecting the dependent vari-
able, drug use. Variance cannot be attributed to a constant.
EPIDEMIOLOGY AS AN ORGANIZING FRAMEWORK
The organizing conceptual framework for this paper is provided by
epidemiology, of which there are at least three types: classical,
psychiatric, and social. Classical epidemiology derives from a
medical orientation and has usually been employed to trace the
course of a disease through a population. Excellent examples of
the application of classical epidemiology in the study of drug
abuse are the investigations of De Alarcon (1969). Levengood et
al. (1973), and Hughes et al. (1971) on the spread of heroin
through communities.
Psychiatric epidemiology involves an application of classical
(medical) techniques of tracing the spread of a phenomenon through
a population, but adds diagnostic confirmational criteria to
validate and further describe the particular phenomenon under
study. For example, it may be important in studying drug use to
confirm whether a drug was taken medically or illicitly. As
Robins (1984) notes, what distinguishes drug abuse from infectious
diseases as the focus of epidemiological research is "the willing-
ness of the host to participate, at least at first."
Social epidemiology, in this paper, is the conceptual framework
for examining gender differences in drug use. Social epidemiology
is generally survey-based and is focused on a large geopolitical
area rather than a single community. The principal functions of
such studies are to provide a description. not only of the extent
of the problem, but also its nature. The components as well as
the size of the problem are measured to detect new aspects of the
problem and to chart changes or trends. Social epidemiological
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studies of drug use provide a picture of who is using what, at
what frequency, and with what acute consequences. Social epidemi-
ology is more useful for generating than testing hypotheses. One
of the most useful functions of social epidemiological studies of
drug use is to evaluate the accuracy of cornnonsense perceptions of
the scope and nature of a social problem such as drug use.
LIFETIME PREVALENCE OF DRUG USE
Drug use is complex and difficult to study. The least precise,
but most frequently measured dimension of drug involvement is
lifetime prevalence, the use of one or more drugs over the course
of a person's life. The data in table 1 are of this kind and
show, by both gender and age group, the epidemic of drug use that
occurred in the United States beginning in the mid-1960s, the
epidemic related to the passage of the so-called "baby boom gener-
ation." Two of the age groups (18 to 25 and 26 to 34 years old)
roughly correspond to the baby boom birth cohorts, or persons born
in the years 1948 through 1964.
On the basis of earlier research, it would be hypothesized that
the lifetime prevalence of use of illicit substances will be
higher among males than females, while the prevalence of medical
use of psychotherapeutics will be higher among females than males
(Mellinger and Balter 1981; Yamaguchi and Kandel 1984).
Further, the prevalence rates for use of illicit drugs would be
expected to be higher for individuals in the two baby boom age
groups than for persons younger or older. Among youth, lower
rates would be anticipated because initiation of drug use is
developmental in character, building from one to several drugs
and from infrequent to more frequent use. Lower rates would be
expected among older individuals because they had entered adult
roles when the drug epidemic of the 1960s and 1970s began. On the
other hand, Mellinger and Balter (1981) suggest that the probabil-
ity of using psychotherapeutic drugs increases with age, so that
the prevalence rates for these drugs might be expected to be high-
est in the oldest age category.
Checking these assumptions against the 1982 survey data, we find
agreement with expectations, with some exceptions. In table 1, 32
comparisons of males and females with respect to the use of il-
licit drugs can be made. The males, as expected, have the higher
prevalence rate except for categories of prescribed drugs, regard-
less of age group. Furthermore, the rates for use of illicit
drugs are higher in the two baby boom age groups, regardless of
gender, also as expected.
The instances in which the hypotheses are not supported are in the
use of prescription psychotherapeutics among youth, where in three
of the four comparisons, males have slightly higher rates of use
of prescription sedatives, stimulants, and analgesics. Females,
however, show higher use of prescribed tranquilizers in most
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TABLE 1. Lifetime prevalence of various drugs by age group and
gender: 1982 Rational Survey on Drug Abuse
a. Youth, 12 to 17 years old in 1982, were born in 1965-70.
b. Young Adults, 18 to 25 years old in 1982, were born In 1957-64.
c. Mid-Adults, 26 to 34 years old in 1982, were born in 1948-56.
d. Older Adults, 35 years old or over in 1982, were born prior to 1948.
categories, as expected. If one allows for reasonable margins of
error, male and female youth do not differ in terms of lifetime
use of these four classes of drugs.
Contrary to expectations, the highest rates for psychotherapeutics
are not uniformly found among the respondents in the oldest age
group. It should be noted that the lifetime prevalence rates for
some of the psychotherapeutics are quite high. For example,
almost one-half of the females who are 35 or older have used tran-
quilizers medically, and 50 percent of these women have used anal-
gesics medically. Further, the rates are somewhat higher among
the women 18 to 25 and 26 to 34. While it would be inappropriate
to interpret these data as evidence of abuse of these drugs, such
high prevalence rates show that a substantial proportion of women
age 35 and older are "at risk" for progression toward abusive
patterns of use. It is, therefore, important to examine the fre-
quency or extent to which these four classes of drugs are used by
men and women, as well as how they are used (e.g., nonmedically
only, medically only, both medically and nonmedically).
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FREQUENCY OF USE
There is little consensus regarding what constitutes frequent or
abusive use of drugs and, as one might expect, the criteria vary
by class of drug. Because the literature offers few guidelines,
an arbitrary decision was made to classify "more frequent" users
according to the following definitions:
for cigarettes, if they smoked a pack or more each day during
the preceding 30 days;
for marijuana, if they smoked during 10 or more days of the
past 30 days;
for alcohol, if they drank on 10 or more days of the past 30
days;
for cocaine, if they used on 5 or more days of the past 30
days.
The data shown in table 2 reveal that patterned differences by sex
exist when these criteria are applied. Almost three times as many
adult men as women report using marijuana on 10 or more days
during the preceding month. The ratio for alcohol use on 10 or
more of the past 30 days is about 2.7 to 1. Thus, gender differ-
ences in drug use exist and are in the expected direction for this
sample, whether the measure is lifetime prevalence or more
frequent use of licit and illicit drugs.
MEDICAL AND NONMEDICAL USE OF PSYCHOTHERAPEUTICS
Some classes of drugs serve legitimate medical functions and are
obtained primarily through prescriptions. These drugs can also be
used nonmedically, or in ways inconsistent with the physician's
instructions despite being obtained from a pharmacy. Persons who
obtain drugs other than by means of a prescription are nonmedical
users by definition, but it is also possible to misuse a properly
prescribed drug, which is to use it nonmedically. In the 1982
National Survey, questions were posed that dealt with the medical
and nonmedical use of sedatives, tranquilizers, stimulants, and
analgesics.
The data shown in table 3 provide evidence concerning gender dif-
ferences in the use of psychotherapeutic drugs by age group. A
word of caution is necessary before these data are discussed. The
figures are percentages of those who have "ever used" the partic-
ular substances, not percentages of the total sample. With this
caveat in mind, the data in adjacent columns can be used to ad-
dress important hypotheses about gender differences in drug use.
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TABLE 2. Recent, more frequent use of cigarettes, alcohol,
marijuana, and cocaine, by age group and gender: 1982
National Survey on Drug Abuse
a. Youth, 12 to 17 years old in 1982, were born in 1965-70.
b. Young Adults, 18 to 25 years old in 1982, were born in 1957-64.
c. Mid-Adults, 26 to 34 years old in 1982, were born In 1948-56.
d. Older Adults, 35 years old or over in 1982, were born prior to 1948.
As predicted, women are generally more likely than men to report
medical use of psychotherapeutics except for youthful and older
respondents, where the gender difference is reversed or smaller.
Of the 16 comparisons, the only reversed gender difference is in
use of stimulants by youth, 29 percent of males compared to 17
percent of females, but small or near zero gender differences
appear for youth and older adults. It should be noted again that
these percentages refer only to those who have ever used stimu-
lants, not to all youth.
Forgetting prescribed medical use for now to look at gender dif-
ferences in nonmedical use of psychotherapeutics (table 3), we
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TABLE 3. Percent of "ever users" of four classes of psycho-
therapeutics who report use nonmedically only, only by
prescription, and both medically and nonmedically by
age group and gender: 1982 National Survey on Drug
Abuse
a. Youth, 12 to 17 years old in 1982, were born in 1965-70.
b. Young Adults, 18 to 25 years old in 1982, were born in 1957-64.
c. Mid-Adults, 26 to 34 years old in 1982, were born in 1948-56.
d. Older Adults, 35 years old or over in 1982, were born prior to 1948.
find males predominating, as expected, except in three instances--
sedatives, stimulants, and analgesics among youth. but the signif-
icance of these exceptions has not been determined.
The expectation that males will be more likely than females to
report using these drugs both medically and nonmedically is sup-
ported by the data. Of 16 possible comparisons, two are excep-
tions to this expectation. Both exceptions occur for stimulants
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for young and mid-adults and involve substantial differences
between males and females. Among young adults, only 1 percent of
the males who have used stimulants report having used both medi-
cally and nonmedically in comparison with 12 percent of the
females. Among mid-adults, 10 percent of males and 20 percent of
females use stimulants both medically and nonmedically.
Overall, these data confirm expectations based on the existing
literature concerning gender differences in the use of the psycho-
therapeutics. It is also apparent that persons in the older age
groups, particularly the oldest group, are most likely to have
used these drugs only in a medical context (see table 3). The ex-
ceptions to the expected patterns cluster in one class of drugs,
the stimulants. There is evidence from the survey of high school
seniors that the proportion of females using stimulants nonmedi-
cally for weight control has increased substantially during the
past 10 years (Johnston et al. 1985). This may account, at least
partially, for the high proportion of young females who report
that they used stimulants only nonmedically.
CONSEQUENCES OF USE OF PSYCHOTHERAPEUTICS
There is a commonsense but untested assumption that use of psycho-
therapeutics by women is related to role-related stress. Stated
differently, women are said to use these drugs in a quasi-medical
way to cope with or to alleviate stress. In the 1982 National
Survey on Drug Abuse, the respondents were asked if they had ever
experienced the following consequences as a result of using the
psychotherapeutic drugs: depression, argumentativeness, auto-
mobile accident, trouble at school, trouble at work, or a medical
emergency. In analyzing these data, the psychotherapeutics were
combined into three mutually exclusive categories: nonmedical
use, medical use, and both medical and nonmedical use. The ques-
tions had been posed with respect to specific drugs, but our
interest was in respondents experience of the consequence, re-
gardless of the specific psychotherapeutic drug producing it. Age
was ignored because the number of positive responses was too small
for a meaningful analysis by age.
Looking at table 4, it is clear that respondents rarely attribute
adverse consequences to the use of psychotherapeutics. The most
prevalent consequence is depression, but it is reported by only
5.9 percent of the males and 7.1 percent of the females who had
ever used the psychotherapeutics. Respondents who used psycho-
therapeutic drugs both medically and nonmedically were more likely
to report depression and argumentativeness than subjects who used
drugs only medically or only nonmedically. There do not seem to
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TABLE 4. Consequences attributed to use of psychotherapeutic
drugs (sedatives, tranquilizers, stimulants,
analgesics) by, type of use and gender: 1982 National
Survey on Drug Abuse
be differences between males and females, except for depression in
respondents who report only nonmedical use of psychotherapeutics.
Few people, however, reported any adverse consequences, and the
sample is too small for reliably measuring small differences.
AGE AT INITIATION OF DRUG USE
Although concern has been expressed that children are initiating
drug use at younger and younger ages, little research has focused
directly on age at onset. Virtually nothing is known about gender
difference in age at onset for abused drugs, including whether or
not it has changed over the years.
In the 1982 National Survey, respondents were asked to specify the
age of first use of various drugs. In presenting the data, a
decision was made to exclude persons between the ages of 12 and 19
because the usual age at onset for the "gateway drugs"--
cigarettes, alcohol, and marijuana--is presumed to occur during
the teens. By starting with persons who have already passed
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through the period during which they are "most at risk," we avoid
the problem of confounding due to differential periods at risk.
Adjacent birth cohorts (e.g., 20 to 21, 22 to 23) were combined to
avoid the problem of small sample size in certain cells of the
table. It was decided not to present age at onset for age groups
in which less than 10 percent of respondents used the drug.
Finally, medians rather than means are presented because they are
less sensitive to outliers.
These data are relevant to important issues and questions of
public policy:
Is the age at onset of drug use decreasing? If so, for what
drugs?
Have the differences between males and females in age at onset
of drug use changed?
From an epidemiological perspective, is there evidence of an
age, period, or cohort effect with regard to age at onset of
drug use?
The data in tables 5 and 6 show, by gender, the median age at
onset of use, both medical and nonmedical, of a number of drugs
and drug classes--cigarettes, alcohol, marijuana, cocaine, seda-
tives, tranquilizers , stimulants, and analgesics. The ages shown
in these tables reflect midpoints--one-half of the subjects who
report use of that particular drug first used it earlier than the
age shown, while the other half used it later.
Cigarette and Alcohol Use
In every comparison between men and women for cigarettes and
alcohol, the median age at onset of use is higher for women than
it is for men (figure 1). The median age at onset for cigarettes
appears to be rising for males, the average median age being 13.6
for young respondents (12-19) compared to 12.8 for older respond-
ents (58-65). The trend for women is the opposite, with the aver-
age median age being 14.5 for young respondents and 16.6 for older
respondents. It is important to note that although a greater
change occurred among women, the net result is a convergence in
the median age at onset of cigarette use for males and females.
This convergence depends on both women and men changing age at
first use (cigarettes) and in opposite directions.
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TABLE 5. Median age at first use of various drugs: 1982 National Survey on Drug Abuse (males)
TABLE 5. Median age at first use of various drugs: 1982 National Survey on Drug Abuse (females)
FIGURE 1. Median age of onset of cigarettes for males and females
For alcohol, males show no change in their age at first use
(figure 2). For males, initial use of alcohol is a developmental
or age-specific phenomenon. For women, median age at first use of
alcohol has dropped an average of almost 2 years from the oldest
to the youngest four age groups. This suggests an influence of
era, a cohort effect, for females beginning to consume alcohol in
this society.
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FIGURE 2. Median age of  onset of alcohol for males and females
Marijuana and Cocaine
Three findings are apparent from examining the data for marijuana
in tables 5 and 6. First, men in only one age group have less
than 10 percent of respondents reporting marijuana use compared to
four such age groups for women. Second, for both men and women,
the median age at first use of marijuana is related to when the
respondents were born, with younger age groups starting use earli-
er than older respondents. This suggests either a cohort or a
period effect for marijuana use. Third, there is little differ-
ence by gender in the median age at onset of marijuana use. For
example, for each of the cohorts born between 1949-50 and 1961-62,
there Is less than a l-year difference between males and females
in onset of marijuana use.
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For cocaine, also, there is a cohort or a period effect, with the
younger respondents using the drug earlier than the older age
groups. For females there are seven age groups in which less than
10 percent of the respondents report use of cocaine, while for
males there are four. The trend is toward younger men and women
starting use of cocaine. A separate analysis of data from the
1982 National Survey focusing explicitly on cocaine suggests that
an epidemic (i.e., period effect) of cocaine use occurred during
the late 1970s and early 1980s. In fact, 47 percent of the
respondents in the 1982 survey who had ever used cocaine used it
first in 1979, 1980, or 1981 (Clayton 1985).
Nonmedical Use of the Psychotherapeutics
Psychotherapeutics can be used medically or nonmedically, and
several conclusions may be drawn from the data regarding non-
medical use of these drugs. First, young females are the ones
likely to use these drugs nonmedically, whereas older males use
them nonmedically. For example, In only 1 of the 16 age groups
(22 to 23) do more than 10 percent of the female respondents re
port having used analgesics nonmedically. Only women in the five
youngest age groups contain more than 10 percent of respondents
reporting nonmedical use of sedatives and tranquilizers. For
tranquilizers, more than 10 percent report use in the three young-
est age groups. Among these age groups, the median ages at onset
do not differ greatly. For stimulants, 9 of the 16 age groups
contain 10 percent or more women reporting nonmedical use, and
there is little difference in the age at onset in these groups.
Nonmedical use of the psychotherapeutics is more prevalent among
men, and, for each of the four psychotherapeutics, the median age
at onset is similar for the age groups of 20 to 21 through 30 to
31. It appears that age at onset of nonmedical use of psycho-
therapeutics represents a developmental phenomenon for males or a
societal trend away from recreational use of psychotherapeutics.
Among females, nonmedical use is not sufficiently prevalent to
justify a generalization.
Medical Use of the Psychotherapeutics
The clearest gender difference in medical use of psychothera-
peutics is for stimulants. Among males, only 1 of the 16 age
groups has a prevalence above 10 percent. In contrast, females'
medical use of the stimulants is not a rare occurrence. The
median age at onset of stimulant prescriptions is essentially the
same for every age group from 20 to 21 through 30 to 31. This
finding is consistent with the notion that women in these age
groups use stimulants for dieting purposes. The reasons for use
of drugs are, however, not available from the 1982 survey data.
Looking now at medical use of sedatives, use is less prevalent
among males than females, just as it is for stimulants. For both
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males and females, the median age at onset is lower for younger
age groups.
The same trend appears for medical use of tranquilizers and anal-
gesics. Males and females show an earlier median age at onset for
the younger age groups. The age at onset for medical use of all
these drugs seems to be declining.
Onset of drug use is not exclusively an adolescent phenomenon, as
can be seen from the data presented in tables 5 and 6. For exam-
ple, a substantial proportion (21.9 percent) of persons ever using
marijuana or cocaine first used after the age of 20. For males,
the percent starting at age 20 or later is 21.5; for females, it
is 22.8. Thus, the percentage of persons waiting until adulthood
to try these drugs does not differ significantly by gender. These
findings are not consistent with the widely held assumption that
reaching the age of 20 without having used these drugs assures a
future probability of initiation close to zero.
What accounts for this unexpected finding that runs counter to one
of the most commonly held assumptions in the drug abuse field?
Several possible answers exist. First, most data about when drug
use begins comes from samples of adolescents. The annual surveys
of high school seniors, for instance, is based on a sample aged 18
or under. To examine differences in age at onset, a full range of
ages must be studied. To our knowledge, the data pertaining to
age at onset gathered in the series of national surveys sponsored
by NIDA have yet to be analyzed. Second, an era effect may be
confused with a cohort effect. That is, a temporary epidemic of
drug use, in which the median age at onset of drug use differs
between age groups but is similar within age groups, can add to
evidence for adult initiation of drug use. This is in contrast to
a long-term cohort effect, whereby younger age groups show a long-
term or permanent trend to use at an earlier age. One must exam-
ine the years in which new users appear in order to separate these
possibilities. It is possible that women will lag behind men by
an average of a year or more when the data are more closely
analyzed.
DISCUSSION
Patterns of drug use by gender, as analyzed here, confirm some
popular opinions. For example, measured in terms of lifetime
prevalence, rates of drug use are higher among males than fe-
males. In addition, males report more frequent and extensive use
of cigarettes, alcohol, marijuana, and cocaine than do females.
For the psychotherapeutic drugs, men are more likely to obtain
them nonmedically, while women are more likely to obtain these
drugs through medical channels. Median age at onset for older
women was at a later age than for men of comparable age.
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Notable among the younger cohorts is an apparent convergence
between the sexes in the age at initiation of drug use. Specifi-
cally, the median age at onset of cigarette use has Increased
among men and decreased among women, eliminating any gender dif-
ference for respondents 33 or younger. For alcohol, males show a
stable median age at onset across a wide range of birth years.
Females, however, show a decreasing median age at onset that is
almost 2 years lower in the youngest cohorts than in the oldest
cohorts. The pattern of drug use of men and women is becoming
more similar according to these results, which comes as no great
surprise. The explanation of this convergence, however, remains
to be found.
Disconfirming a widely held belief that a person who does not
begin using marijuana during adolescence will not start after age
20, the data show that 22 percent of the respondents in the 1982
National Survey started using marijuana after age 20. No gender
differences show in the percentage of respondents who started to
use marijuana after 20, suggesting a period or era effect when
using the drug may have been the fashion. Although lifetime prev-
alence of marijuana use is sufficiently high in persons under 20
that one might suspect the rate was approaching maximum, over 20
percent of males and females begin use at a later age. For
cocaine, the figure is more striking, with almost 50 percent of
lifetime users starting after age 20. As with marijuana, males
and females show no differences in percent initiating cocaine use
after age 20. The important implication of this finding is that
prevention programs aimed only at the young miss a sizable portion
of the population at risk.
From the perspective of public policy, gender differences exist
for use of several drugs and should be considered in the develop-
ment of prevention and treatment strategies. Treating the "drug
abuser," with little effort to tailor the program to the charac-
teristics of the clients, is known to be inefficient in treating
patients with different psychiatric diagnoses. To the extent that
the gender variable determines patterns of drug use and abuse, it
is reasonable to expect that efficient treatment will attend to
these differences. The data reported in this paper show that men
and women do differ in both how they obtain and how they use
psychotherapeutic drugs.
The Federal research agenda for studying gender as a variable
affecting drug use and abuse can easily be accommodated and is an
important topic for public policy. Some of the gender effects in
substance abuse that require attention are:
the use of stimulants by women, particularly younger women, to
lose weight, and the relationship of such use to anorexia and
bulemia;
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the near and long-term effects of drugs on the reproductive
process, including male reproductive biology, and the
implications for the public health of future generations;
the factors that account for higher levels of physician visits
and prescriptions for women compared to men;
the effects of women's changing role and increasing presence in
the labor force on "patterns" of drug use and abuse; and
the possible link between divorce and substance use.
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